Tissue and cell type-associated traits map for all cell types in [AdultUterus] [link to TSEA][link to UBERON] . Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-05 as default, and users can change it to 1e-04, 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple trait-associated-gene (TAG) sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below. Users could further select to only show the association for those ‘tissue-specfic cell types’ defined from ontology analysis.
Table. List of Tissue-cell type associated traits pairs for [AdultUterus]. If the network above is too complicated, the users could obtain the association information from the table at bottom. Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Cell type | Trait name | Trait full name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|---|
Endothelial cell (APC) | Age At Menarche | Age At Menarche | ETC | Perry | 2014 | NA | 182413 | 5.00e-2 | 8.52e-3 |
Endothelial cell (APC) | Age At Menarche | Age At Menarche | ETC | Perry | 2014 | NA | 182413 | 1.00e-2 | 9.61e-3 |
Endothelial cell (APC) | Age At Menarche | Age At Menarche | ETC | Perry | 2014 | NA | 182413 | 1.00e-3 | 4.48e-2 |
Endothelial cell (APC) | Aggression | Aggression | MTC | Pappa | 2015 | NA | 15668 | 1.00e-2 | 2.96e-2 |
Endothelial cell (APC) | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 5.00e-2 | 4.38e-3 |
Endothelial cell (APC) | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-2 | 1.19e-2 |
Endothelial cell (APC) | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-3 | 3.04e-4 |
Endothelial cell (APC) | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-4 | 1.60e-3 |
Endothelial cell (APC) | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-5 | 5.28e-4 |
Macrophage | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 5.00e-2 | 6.12e-3 |
Macrophage | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-2 | 3.40e-2 |
Macrophage | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-3 | 9.35e-3 |
Macrophage | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-4 | 6.08e-3 |
Macrophage | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-5 | 6.10e-3 |
Stromal cell | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-2 | 4.67e-2 |
Endothelial cell | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-4 | 1.99e-2 |
Endothelial cell | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-5 | 2.83e-3 |
Macrophage | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-5 | 3.93e-3 |
Macrophage | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-3 | 2.42e-2 |
Macrophage | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-4 | 3.61e-3 |
Macrophage | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-5 | 3.15e-2 |
Endothelial cell (APC) | Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | MTC | van-Rheenen | 2016 | 12577 | 23475 | 1.00e-2 | 9.81e-3 |
Fibroblast | Anorexia Nervosa | Anorexia Nervosa | MTC | Boraska | 2014 | 2907 | 14860 | 5.00e-2 | 3.03e-2 |
Endothelial cell | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 5.00e-2 | 6.53e-3 |
Endothelial cell | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-2 | 2.25e-3 |
Endothelial cell | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-3 | 2.56e-3 |
Endothelial cell | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-4 | 1.00e-3 |
Endothelial cell | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-5 | 1.05e-2 |
Endothelial cell (APC) | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 5.00e-2 | 1.95e-2 |
Endothelial cell (APC) | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-2 | 2.25e-3 |
Endothelial cell (APC) | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-3 | 4.46e-4 |
Endothelial cell (APC) | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-4 | 1.03e-4 |
Endothelial cell (APC) | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-5 | 1.12e-3 |
Macrophage | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-2 | 4.64e-2 |
Macrophage | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-3 | 2.37e-2 |
Macrophage | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-4 | 1.00e-3 |
Macrophage | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-5 | 3.59e-3 |
Endothelial cell | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-2 | 2.77e-2 |
Endothelial cell | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-3 | 5.55e-3 |
Endothelial cell | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-4 | 2.61e-2 |
Endothelial cell | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-5 | 4.36e-2 |
Macrophage | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-3 | 3.79e-2 |
Macrophage | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-4 | 7.39e-3 |
Macrophage | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-5 | 9.95e-3 |
Endothelial cell (APC) | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-4 | 2.61e-2 |
Endothelial cell (APC) | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-5 | 4.36e-2 |
Endothelial cell (APC) | Blood Pressure | Blood Pressure | MTC | Ehret | 2011 | NA | 69395 | 1.00e-2 | 6.76e-3 |
Endothelial cell | Blood Pressure | Blood Pressure | MTC | Ehret | 2011 | NA | 69395 | 1.00e-4 | 1.96e-2 |
Endothelial cell (APC) | BMI | Body Mass Index | MTC | Yang | 2012 | NA | 133154 | 1.00e-2 | 4.11e-2 |
Loop of Henle | BMI | Body Mass Index | MTC | Yang | 2012 | NA | 133154 | 1.00e-2 | 9.05e-3 |
Loop of Henle | BMI | Body Mass Index | MTC | Yang | 2012 | NA | 133154 | 1.00e-3 | 1.58e-2 |
Stromal cell | Bone Mineral Density Estimated | Bone Mineral Density Estimated | MTC | Kemp | 2017 | NA | 142487 | 1.00e-5 | 2.56e-2 |
Endothelial cell | Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 5.00e-2 | 2.05e-2 |
Endothelial cell | Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 1.00e-2 | 1.39e-3 |
Stromal cell | Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 5.00e-2 | 2.89e-2 |
Endothelial cell (APC) | Breast Cancer | Breast Cancer | MTC | Hunter | 2007 | NA | 1145 | 1.00e-2 | 1.03e-2 |
Endothelial cell | Cerebral White Matter Hyperintensity | Cerebral White Matter Hyperintensity | MTC | Traylor | 2016 | NA | 3670 | 5.00e-2 | 9.92e-3 |
Fibroblast | Cerebral White Matter Hyperintensity | Cerebral White Matter Hyperintensity | MTC | Traylor | 2016 | NA | 3670 | 5.00e-2 | 1.60e-2 |
Endothelial cell | Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 5.00e-2 | 5.05e-3 |
Macrophage | Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 5.00e-2 | 1.30e-2 |
Endothelial cell (APC) | Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 1.00e-2 | 3.86e-2 |
Endothelial cell | CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 5.00e-2 | 8.01e-4 |
Endothelial cell | CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 1.00e-3 | 1.53e-2 |
Endothelial cell (APC) | CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 5.00e-2 | 2.18e-2 |
Stromal cell | CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 1.00e-2 | 3.99e-2 |
Endothelial cell | CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 5.00e-2 | 3.88e-2 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-3 | 2.68e-2 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-4 | 2.52e-2 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-5 | 1.35e-3 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 5.00e-2 | 1.76e-2 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-3 | 3.42e-2 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-4 | 3.11e-3 |
Smooth muscle cell | CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-5 | 1.58e-2 |
Endothelial cell | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 5.00e-2 | 1.90e-2 |
Endothelial cell | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-2 | 1.51e-2 |
Endothelial cell | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-3 | 7.09e-3 |
Endothelial cell | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-4 | 1.17e-2 |
Endothelial cell (APC) | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 5.00e-2 | 1.23e-3 |
Endothelial cell (APC) | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-2 | 2.21e-2 |
Endothelial cell (APC) | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-3 | 2.06e-2 |
Macrophage | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-2 | 4.49e-2 |
Endothelial cell | CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 5.00e-2 | 2.96e-2 |
Endothelial cell (APC) | CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 5.00e-2 | 1.96e-2 |
Endothelial cell (APC) | CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 1.00e-2 | 2.87e-2 |
Endothelial cell (APC) | CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 1.00e-3 | 2.94e-4 |
Macrophage | CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 1.00e-2 | 2.87e-2 |
Loop of Henle | Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-2 | 4.75e-2 |
Macrophage | Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-5 | 1.55e-2 |
Endothelial cell | Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-3 | 3.86e-2 |
Endothelial cell | Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 1.00e-3 | 3.86e-2 |
Endothelial cell (APC) | Head Circumference | Head Circumference | MTC | Taal | 2012 | NA | 10768 | 5.00e-2 | 3.21e-2 |
Endothelial cell (APC) | Head Circumference | Head Circumference | MTC | Taal | 2012 | NA | 10768 | 1.00e-2 | 1.69e-3 |
Endothelial cell (APC) | Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 5.00e-2 | 4.58e-2 |
Endothelial cell (APC) | Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-2 | 6.21e-3 |
Endothelial cell (APC) | Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-3 | 1.07e-2 |
Stromal cell | Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 5.00e-2 | 2.14e-2 |
Endothelial cell | Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 5.00e-2 | 1.64e-2 |
Endothelial cell (APC) | Internalizing Problems | Internalizing Problems | ETC | Benke | 2014 | NA | 4596 | 1.00e-2 | 3.43e-2 |
Endothelial cell (APC) | MDD | Major Depressive Disorder | MTC | PGC | 2013 | 9240 | 9519 | 5.00e-2 | 3.83e-2 |
Fibroblast | MDD | Major Depressive Disorder | ETC | Wray | 2018 | 16823 | 25632 | 1.00e-2 | 2.02e-2 |
Stromal cell | Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-2 | 7.07e-3 |
Stromal cell | Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-3 | 8.78e-3 |
Stromal cell | Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-4 | 1.25e-2 |
Stromal cell | Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-5 | 1.02e-2 |
Endothelial cell | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 5.00e-2 | 7.66e-4 |
Endothelial cell | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-2 | 6.32e-3 |
Endothelial cell | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-3 | 1.62e-4 |
Endothelial cell | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-4 | 1.52e-4 |
Endothelial cell | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-5 | 2.13e-4 |
Endothelial cell (APC) | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 5.00e-2 | 4.39e-3 |
Endothelial cell (APC) | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-2 | 2.65e-3 |
Endothelial cell (APC) | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-3 | 2.77e-3 |
Endothelial cell (APC) | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-4 | 1.54e-2 |
Endothelial cell (APC) | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-5 | 6.19e-3 |
Macrophage | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-5 | 2.58e-2 |
Endothelial cell | Neuroticism | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 4.68e-2 |
Endothelial cell | Neuroticism | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-3 | 4.90e-2 |
Fibroblast | Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-3 | 3.60e-2 |
Fibroblast | Neuroticism Symptoms | Neuroticism Symptoms | ETC | Okbay | 2016 | NA | 170911 | 5.00e-2 | 7.52e-3 |
Endothelial cell (APC) | Neuroticism Symptoms | Neuroticism Symptoms | ETC | Okbay | 2016 | NA | 170911 | 1.00e-2 | 4.32e-2 |
Macrophage | Neuroticism Symptoms | Neuroticism Symptoms | ETC | Okbay | 2016 | NA | 170911 | 1.00e-4 | 3.56e-2 |
Endothelial cell | Offspring Birth Weight | Offspring Birth Weight | MTC | Beaumont | 2018 | NA | 68258 | 1.00e-4 | 2.89e-2 |
Macrophage | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-2 | 2.42e-2 |
Macrophage | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-3 | 4.60e-2 |
Macrophage | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-4 | 8.44e-3 |
Endothelial cell (APC) | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-4 | 8.44e-3 |
Endothelial cell | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 5.00e-2 | 2.15e-2 |
Endothelial cell | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-2 | 2.44e-4 |
Endothelial cell | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-3 | 1.19e-4 |
Endothelial cell | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-4 | 1.07e-4 |
Endothelial cell | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-5 | 1.71e-4 |
Endothelial cell (APC) | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 5.00e-2 | 2.15e-2 |
Endothelial cell (APC) | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-2 | 3.07e-2 |
Endothelial cell (APC) | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-3 | 7.61e-4 |
Endothelial cell (APC) | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-4 | 1.07e-4 |
Endothelial cell (APC) | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-5 | 5.18e-5 |
Loop of Henle | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 5.00e-2 | 4.24e-2 |
Macrophage | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-3 | 7.61e-4 |
Macrophage | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-4 | 3.38e-5 |
Macrophage | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-5 | 1.71e-4 |
Endothelial cell (APC) | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 5.00e-2 | 4.96e-2 |
Endothelial cell (APC) | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-2 | 2.68e-2 |
Endothelial cell (APC) | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-3 | 1.15e-2 |
Endothelial cell (APC) | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-4 | 1.28e-2 |
Endothelial cell (APC) | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-5 | 1.22e-2 |
Endothelial cell | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-2 | 4.51e-2 |
Endothelial cell | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 5.00e-2 | 1.26e-2 |
Endothelial cell | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-2 | 1.12e-2 |
Endothelial cell | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-3 | 1.22e-4 |
Endothelial cell | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-4 | 9.27e-5 |
Endothelial cell | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-5 | 4.24e-5 |
Endothelial cell (APC) | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 5.00e-2 | 1.26e-2 |
Endothelial cell (APC) | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-2 | 3.43e-3 |
Endothelial cell (APC) | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-3 | 3.39e-4 |
Endothelial cell (APC) | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-4 | 2.66e-5 |
Endothelial cell (APC) | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-5 | 4.24e-5 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-2 | 6.32e-3 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-3 | 3.39e-4 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-4 | 9.27e-5 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-5 | 5.28e-4 |
Endothelial cell | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-3 | 1.70e-2 |
Endothelial cell (APC) | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-3 | 3.19e-2 |
Endothelial cell (APC) | Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 5.00e-2 | 1.72e-3 |
Endothelial cell (APC) | Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 1.00e-2 | 3.68e-2 |
Smooth muscle cell | Sleep Duration BMI Adjusted | Sleep Duration BMI Adjusted | MTC | Marinelli | 2016 | NA | 10554 | 1.00e-2 | 3.60e-2 |
Smooth muscle cell | Sleep Duration BMI Adjusted | Sleep Duration BMI Adjusted | MTC | Marinelli | 2016 | NA | 10554 | 1.00e-3 | 1.88e-2 |
Macrophage | Sleep Duration BMI Adjusted | Sleep Duration BMI Adjusted | MTC | Marinelli | 2016 | NA | 10554 | 1.00e-2 | 3.60e-2 |
Endothelial cell | Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 5.00e-2 | 4.90e-3 |
Fibroblast | Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 1.00e-2 | 3.43e-2 |
Endothelial cell (APC) | Type 2 Diabetes | Type 2 Diabetes | ETC | Morris | 2012 | 12171 | 56862 | 1.00e-2 | 4.10e-2 |
Endothelial cell (APC) | Type 2 Diabetes | Type 2 Diabetes | ETC | Morris | 2012 | 12171 | 56862 | 1.00e-3 | 5.63e-3 |
Endothelial cell | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 5.00e-2 | 5.73e-3 |
Endothelial cell | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-2 | 5.86e-4 |
Endothelial cell | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-3 | 2.92e-4 |
Endothelial cell | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-4 | 6.04e-4 |
Endothelial cell | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-5 | 3.81e-3 |
Macrophage | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 5.00e-2 | 2.77e-3 |
Macrophage | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-2 | 7.26e-3 |
Macrophage | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-3 | 5.16e-3 |
Macrophage | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-4 | 8.61e-5 |
Macrophage | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-5 | 1.55e-4 |
Endothelial cell (APC) | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-4 | 3.45e-3 |
Endothelial cell (APC) | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-5 | 3.81e-3 |
Endothelial cell | Vitamin D | Vitamin D | MTC | Manousaki | 2017 | NA | 42274 | 5.00e-2 | 2.70e-2 |
Stromal cell | Vitamin D | Vitamin D | MTC | Manousaki | 2017 | NA | 42274 | 5.00e-2 | 6.99e-4 |
Stromal cell | Vitamin D | Vitamin D | MTC | Manousaki | 2017 | NA | 42274 | 1.00e-2 | 1.22e-3 |
Endothelial cell (APC) | Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 5.00e-2 | 2.44e-2 |
Endothelial cell (APC) | Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 1.00e-2 | 1.01e-2 |
Endothelial cell (APC) | Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 1.00e-3 | 1.79e-3 |
Endothelial cell (APC) | Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 1.00e-4 | 2.61e-2 |
Endothelial cell (APC) | Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 1.00e-5 | 4.89e-3 |
Macrophage | Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 1.00e-5 | 2.57e-2 |
Endothelial cell | Warfarin maintenance dose | Warfarin maintenance dose | MTC | Cooper | 2008 | NA | 181 | 5.00e-2 | 3.63e-2 |
Endothelial cell (APC) | Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Boger | 2011 | NA | 31580 | 1.00e-3 | 3.40e-2 |
Endothelial cell | Albuminuria | Microalbuminuria | MTC | Teumer | 2016 | NA | 54116 | 1.00e-2 | 1.29e-3 |
Endothelial cell (APC) | Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Teumer | 2016 | NA | 54450 | 5.00e-2 | 1.60e-3 |
Endothelial cell (APC) | Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Teumer | 2016 | NA | 54450 | 1.00e-2 | 1.43e-2 |
Loop of Henle | Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Teumer | 2016 | NA | 54450 | 1.00e-2 | 1.43e-2 |
Smooth muscle cell | Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 5.00e-2 | 6.19e-3 |
Endothelial cell (APC) | Albuminuria | Urinary Albumin to Creatinine Ratio In Nondiabetics | MTC | Teumer | 2016 | NA | 46051 | 5.00e-2 | 3.28e-2 |
Endothelial cell (APC) | Albuminuria | Urinary Albumin to Creatinine Ratio In Nondiabetics | MTC | Teumer | 2016 | NA | 46051 | 1.00e-2 | 4.96e-2 |
Loop of Henle | Alcohol Consumption | Alcohol Consumption Men Continuous | MTC | Schumann | 2016 | NA | 27560 | 5.00e-2 | 9.59e-3 |
Endothelial cell (APC) | Alcohol Consumption | Alcohol Consumption Men Dichotomous | MTC | Schumann | 2016 | NA | 26991 | 5.00e-2 | 1.98e-2 |
Fibroblast | Alcohol Consumption | Alcohol Consumption Women Dichotomous | MTC | Schumann | 2016 | NA | 47720 | 5.00e-2 | 1.27e-2 |
Endothelial cell | Alzheimers Protein Levels | Amyloid Beta 1 42 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 4.28e-2 |
Fibroblast | Alzheimers Protein Levels | Amyloid Beta 1 42 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 1.67e-3 |
Stromal cell | Alzheimers Protein Levels | Amyloid Beta 1 42 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 2.89e-2 |
Loop of Henle | Alzheimers Protein Levels | Amyloid Beta 1 42 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 1.23e-2 |
Endothelial cell (APC) | Alzheimers Protein Levels | Phosphorylated Tau Position 181 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 2.98e-3 |
Endothelial cell (APC) | Alzheimers Protein Levels | Phosphorylated Tau Position 181 | MTC | Ramirez | 2014 | NA | 363 | 1.00e-3 | 2.02e-2 |
Stromal cell | Anthropometric Extremes | Extreme Height | MTC | Berndt | 2013 | 8097 | 8099 | 5.00e-2 | 1.39e-2 |
Endothelial cell (APC) | Anthropometric Extremes | Extreme Waist Hip Ratio | MTC | Berndt | 2013 | 4774 | 5481 | 1.00e-2 | 8.44e-3 |
Loop of Henle | Anthropometrics Sex Stratified | Body Mass Index Women | MTC | Randall | 2013 | NA | 73137 | 5.00e-2 | 3.25e-2 |
Endothelial cell (APC) | Anthropometrics Sex Stratified | Height Men | MTC | Randall | 2013 | NA | 60856 | 5.00e-2 | 4.09e-2 |
Endothelial cell (APC) | Anthropometrics Sex Stratified | Height Men | MTC | Randall | 2013 | NA | 60856 | 1.00e-4 | 3.24e-2 |
Stromal cell | Anthropometrics Sex Stratified | Height Men | MTC | Randall | 2013 | NA | 60856 | 1.00e-3 | 2.97e-2 |
Endothelial cell | Anthropometrics Sex Stratified | Hip Circumference Women | MTC | Randall | 2013 | NA | 43316 | 1.00e-3 | 4.36e-2 |
Endothelial cell (APC) | Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 45192 | 1.00e-2 | 7.60e-3 |
Endothelial cell | Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Men | MTC | Randall | 2013 | NA | 34629 | 1.00e-2 | 4.83e-2 |
Endothelial cell (APC) | Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Women | MTC | Randall | 2013 | NA | 42969 | 5.00e-2 | 2.59e-2 |
Endothelial cell (APC) | Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Women | MTC | Randall | 2013 | NA | 42969 | 1.00e-2 | 1.93e-2 |
Endothelial cell (APC) | Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Women | MTC | Randall | 2013 | NA | 42969 | 1.00e-4 | 9.95e-3 |
Stromal cell | Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Women | MTC | Randall | 2013 | NA | 42969 | 5.00e-2 | 2.59e-2 |
Endothelial cell | Anthropometrics Sex Stratified | Waist Hip Ratio Women | MTC | Randall | 2013 | NA | 42969 | 5.00e-2 | 4.33e-2 |
Endothelial cell (APC) | Anthropometrics Sex Stratified | Waist Hip Ratio Women | MTC | Randall | 2013 | NA | 42969 | 5.00e-2 | 4.40e-3 |
Loop of Henle | Anthropometrics Sex Stratified | Weight Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-5 | 2.57e-2 |
Smooth muscle cell | Aortic Valve Calcification | Aortic Valve Calcification | MTC | Thanassoulis | 2013 | NA | 6942 | 1.00e-2 | 2.79e-2 |
Endothelial cell | Birth Weight | Birth Weight European | ETC | Horikoshi | 2016 | NA | 133903 | 1.00e-2 | 1.19e-3 |
Endothelial cell (APC) | Birth Weight | Birth Weight European | ETC | Horikoshi | 2016 | NA | 133903 | 1.00e-2 | 2.90e-3 |
Endothelial cell (APC) | Birth Weight | Birth Weight European | ETC | Horikoshi | 2016 | NA | 133903 | 1.00e-3 | 2.57e-2 |
Endothelial cell (APC) | Birth Weight | Birth Weight European | ETC | Horikoshi | 2016 | NA | 133903 | 1.00e-4 | 1.45e-2 |
Endothelial cell (APC) | Blood Cells | Eosinophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.25e-2 |
Endothelial cell (APC) | Blood Cells | Hematocrit | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.16e-2 |
Macrophage | Blood Cells | Hematocrit | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 3.93e-2 |
Endothelial cell | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.19e-3 |
Endothelial cell | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 3.45e-3 |
Endothelial cell (APC) | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 2.34e-4 |
Endothelial cell (APC) | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 3.98e-5 |
Endothelial cell (APC) | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-4 | 3.24e-3 |
Loop of Henle | Blood Cells | Mean Corpuscular Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 3.22e-2 |
Endothelial cell | Blood Cells | Mean Corpuscular Hemoglobin Concentration | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 9.83e-3 |
Macrophage | Blood Cells | Mean Corpuscular Hemoglobin Concentration | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 4.83e-2 |
Endothelial cell | Blood Cells | Monocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.08e-2 |
Stromal cell | Blood Cells | Monocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.08e-2 |
Endothelial cell (APC) | Blood Cells | Monocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 3.54e-2 |
Endothelial cell | Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 9.92e-3 |
Endothelial cell | Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 2.68e-2 |
Endothelial cell | Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 4.90e-2 |
Endothelial cell (APC) | Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.03e-3 |
Loop of Henle | Blood Cells | Platelet Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.92e-2 |
Fibroblast | Blood Cells | Red Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.37e-3 |
Endothelial cell | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 3.01e-2 |
Endothelial cell | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 5.86e-4 |
Endothelial cell | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 3.88e-3 |
Endothelial cell (APC) | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.26e-2 |
Endothelial cell (APC) | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 1.41e-3 |
Endothelial cell (APC) | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 2.54e-4 |
Loop of Henle | Blood Lipids | High Density Lipoprotein | ETC | Teslovich | 2010 | NA | 99900 | 5.00e-2 | 3.67e-3 |
Endothelial cell (APC) | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 5.00e-2 | 1.39e-2 |
Endothelial cell (APC) | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-3 | 2.87e-2 |
Endothelial cell (APC) | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-5 | 3.58e-2 |
Macrophage | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-2 | 4.11e-3 |
Macrophage | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-4 | 1.58e-2 |
Macrophage | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-5 | 3.58e-2 |
Endothelial cell (APC) | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 5.00e-2 | 6.17e-3 |
Endothelial cell (APC) | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-2 | 7.25e-3 |
Endothelial cell (APC) | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-3 | 2.25e-2 |
Endothelial cell (APC) | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-4 | 6.78e-3 |
Fibroblast | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-3 | 3.76e-2 |
Fibroblast | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-4 | 2.47e-2 |
Macrophage | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-5 | 1.23e-2 |
Endothelial cell (APC) | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 1.00e-2 | 4.60e-2 |
Endothelial cell (APC) | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 1.00e-3 | 1.70e-2 |
Endothelial cell (APC) | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 1.00e-4 | 2.67e-2 |
Loop of Henle | Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 1.33e-3 |
Endothelial cell (APC) | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 6.82e-3 |
Endothelial cell (APC) | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 2.94e-2 |
Endothelial cell (APC) | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 2.56e-2 |
Endothelial cell (APC) | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 3.70e-2 |
Macrophage | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 1.23e-2 |
Macrophage | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 4.45e-4 |
Macrophage | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 3.79e-4 |
Macrophage | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 6.70e-4 |
Endothelial cell (APC) | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 1.07e-2 |
Endothelial cell (APC) | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 1.31e-2 |
Endothelial cell (APC) | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 1.66e-2 |
Endothelial cell (APC) | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 3.37e-3 |
Endothelial cell (APC) | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 5.06e-3 |
Fibroblast | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 2.74e-2 |
Fibroblast | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 2.23e-2 |
Macrophage | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 4.37e-2 |
Macrophage | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 6.58e-3 |
Macrophage | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 1.03e-2 |
Endothelial cell (APC) | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 1.63e-2 |
Endothelial cell (APC) | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 2.99e-2 |
Endothelial cell (APC) | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 2.10e-2 |
Macrophage | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 3.93e-2 |
Endothelial cell | BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Men Under 50 | MTC | Winkler | 2015 | NA | 43776 | 5.00e-2 | 1.73e-2 |
Fibroblast | BMI Physical Activity Interaction | BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 4.78e-2 |
Endothelial cell (APC) | BMI Physical Activity Interaction | BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.72e-2 |
Macrophage | BMI Physical Activity Interaction | BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.72e-2 |
Loop of Henle | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 4.61e-2 |
Stromal cell | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 1.92e-2 |
Endothelial cell (APC) | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.72e-2 |
Macrophage | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 4.84e-2 |
Smooth muscle cell | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 3.44e-2 |
Stromal cell | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 4.60e-2 |
Stromal cell | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 2.94e-2 |
Endothelial cell (APC) | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 4.33e-2 |
Endothelial cell | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 2.30e-2 |
Loop of Henle | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 4.90e-2 |
Stromal cell | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 2.85e-2 |
Macrophage | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 2.85e-2 |
Macrophage | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 3.56e-2 |
Endothelial cell (APC) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 2.15e-4 |
Endothelial cell (APC) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 1.71e-2 |
Endothelial cell (APC) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 4.81e-3 |
Endothelial cell (APC) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 6.17e-4 |
Endothelial cell (APC) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 1.73e-2 |
Fibroblast | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 1.73e-2 |
Endothelial cell (APC) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 3.82e-2 |
Loop of Henle | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 3.82e-2 |
Endothelial cell (APC) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 9.14e-3 |
Endothelial cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 9.54e-3 |
Endothelial cell (APC) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 5.82e-4 |
Endothelial cell (APC) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 7.48e-4 |
Endothelial cell (APC) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 1.66e-3 |
Endothelial cell (APC) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 4.83e-3 |
Endothelial cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 4.08e-2 |
Endothelial cell (APC) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 1.86e-2 |
Endothelial cell (APC) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 8.97e-3 |
Endothelial cell (APC) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 5.07e-3 |
Endothelial cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 3.43e-2 |
Endothelial cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 1.74e-2 |
Endothelial cell (APC) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 3.42e-3 |
Stromal cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 3.43e-2 |
Endothelial cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 4.25e-2 |
Macrophage | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 4.06e-2 |
Stromal cell | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 4.55e-2 |
Stromal cell | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 1.71e-2 |
Stromal cell | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 3.99e-2 |
Stromal cell | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-5 | 3.24e-3 |
Endothelial cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 4.26e-2 |
Endothelial cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 4.86e-2 |
Endothelial cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 4.44e-3 |
Endothelial cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 3.48e-3 |
Endothelial cell (APC) | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.14e-2 |
Endothelial cell (APC) | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 1.33e-3 |
Endothelial cell (APC) | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 1.22e-3 |
Endothelial cell (APC) | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 1.52e-3 |
Endothelial cell (APC) | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 2.20e-4 |
Stromal cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 1.16e-2 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 1.16e-2 |
Endothelial cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.71e-2 |
Endothelial cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 5.55e-3 |
Endothelial cell (APC) | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.07e-3 |
Endothelial cell (APC) | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 5.55e-3 |
Endothelial cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 3.70e-2 |
Endothelial cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 1.02e-2 |
Endothelial cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 1.66e-2 |
Endothelial cell (APC) | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 9.23e-3 |
Endothelial cell (APC) | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 2.68e-2 |
Endothelial cell (APC) | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 4.60e-2 |
Smooth muscle cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 4.49e-2 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 1.66e-2 |
Macrophage | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 7.39e-3 |
Stromal cell | Bone Mineral Density | Lumbar Spine Bone Mineral Density All | MTC | Estrada | 2012 | NA | 31800 | 5.00e-2 | 2.63e-2 |
Stromal cell | Bone Mineral Density | Lumbar Spine Bone Mineral Density All | MTC | Estrada | 2012 | NA | 31800 | 1.00e-3 | 3.42e-2 |
Loop of Henle | Bone Mineral Density | Lumbar Spine Bone Mineral Density All | MTC | Estrada | 2012 | NA | 31800 | 1.00e-5 | 5.76e-3 |
Macrophage | Bone Mineral Density | Lumbar Spine Bone Mineral Density Men | MTC | Estrada | 2012 | NA | 31800 | 1.00e-3 | 3.75e-2 |
Loop of Henle | Bone Mineral Density | Lumbar Spine Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 31800 | 1.00e-4 | 3.44e-2 |
Loop of Henle | Bone Mineral Density | Lumbar Spine Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 31800 | 1.00e-5 | 2.70e-3 |
Loop of Henle | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 15 to 30 | MTC | Medina-Gomez | 2018 | NA | 4180 | 1.00e-2 | 3.75e-2 |
Endothelial cell | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 45 to 60 | MTC | Medina-Gomez | 2018 | NA | 18805 | 5.00e-2 | 3.72e-2 |
Loop of Henle | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 45 to 60 | MTC | Medina-Gomez | 2018 | NA | 18805 | 1.00e-5 | 4.79e-2 |
Stromal cell | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-3 | 3.53e-2 |
Loop of Henle | Bone Mineral Density | Femoral Neck Bone Mineral Density | ETC | Zheng | 2015 | NA | 26320 | 1.00e-3 | 1.96e-2 |
Stromal cell | Bone Mineral Density | Forearm Bone Mineral Density | ETC | Zheng | 2015 | NA | 6627 | 5.00e-2 | 2.08e-2 |
Loop of Henle | Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 1.00e-2 | 2.51e-2 |
Loop of Henle | Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 1.00e-3 | 1.89e-2 |
Loop of Henle | Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 1.00e-4 | 4.80e-3 |
Loop of Henle | Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 1.00e-5 | 1.77e-3 |
Fibroblast | Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 1.00e-5 | 3.22e-2 |
Endothelial cell (APC) | Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-3 | 2.17e-2 |
Endothelial cell (APC) | Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-4 | 1.42e-3 |
Endothelial cell (APC) | Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-5 | 5.71e-3 |
Fibroblast | Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-3 | 4.33e-2 |
Fibroblast | Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-4 | 1.83e-2 |
Fibroblast | Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-5 | 4.49e-2 |
Stromal cell | Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-3 | 4.33e-2 |
Stromal cell | Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-4 | 7.10e-3 |
Stromal cell | Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-5 | 2.82e-2 |
Endothelial cell (APC) | Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 5.00e-2 | 3.23e-2 |
Smooth muscle cell | Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-2 | 4.10e-2 |
Smooth muscle cell | Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-3 | 2.83e-2 |
Smooth muscle cell | Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-4 | 6.62e-3 |
Smooth muscle cell | Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-5 | 1.26e-3 |
Smooth muscle cell | Coronary Artery Disease | Coronary Artery Disease Recessive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-2 | 2.51e-2 |
Endothelial cell | Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 5.00e-2 | 3.37e-2 |
Smooth muscle cell | Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 1.00e-3 | 3.04e-3 |
Smooth muscle cell | Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 1.00e-4 | 2.44e-3 |
Smooth muscle cell | Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 1.00e-5 | 1.05e-3 |
Loop of Henle | Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 1.00e-3 | 1.37e-2 |
Macrophage | Diarrhoeal Disease | Diarrhea Age 1 | MTC | Bustamante | 2016 | 2693 | 3065 | 5.00e-2 | 4.08e-2 |
Fibroblast | Diarrhoeal Disease | Diarrhea Age 1 | MTC | Bustamante | 2016 | 2693 | 3065 | 1.00e-2 | 3.77e-2 |
Endothelial cell | Diarrhoeal Disease | Diarrhea Age 2 | MTC | Bustamante | 2016 | 2855 | 2753 | 1.00e-2 | 3.21e-2 |
Smooth muscle cell | Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 1 | MTC | Bustamante | 2016 | 1339 | 5064 | 1.00e-2 | 4.61e-2 |
Endothelial cell (APC) | Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 2 | MTC | Bustamante | 2016 | 990 | 5243 | 1.00e-2 | 2.51e-2 |
Loop of Henle | Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 2 | MTC | Bustamante | 2016 | 990 | 5243 | 1.00e-3 | 2.58e-2 |
Macrophage | Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 2 | MTC | Bustamante | 2016 | 990 | 5243 | 1.00e-3 | 2.58e-2 |
Smooth muscle cell | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 1.00e-3 | 4.78e-2 |
Endothelial cell | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14668 | 5.00e-2 | 4.31e-3 |
Endothelial cell | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14668 | 1.00e-2 | 2.01e-2 |
Endothelial cell (APC) | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14668 | 1.00e-2 | 3.93e-2 |
Endothelial cell | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Men | MTC | Chu | 2017 | NA | 7050 | 1.00e-2 | 1.20e-2 |
Smooth muscle cell | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-2 | 4.69e-2 |
Endothelial cell | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14668 | 1.00e-3 | 3.22e-2 |
Endothelial cell | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7050 | 1.00e-2 | 1.71e-3 |
Endothelial cell (APC) | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7618 | 5.00e-2 | 4.89e-2 |
Stromal cell | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7618 | 5.00e-2 | 4.89e-2 |
Smooth muscle cell | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-3 | 3.86e-2 |
Smooth muscle cell | Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation All | MTC | Chu | 2017 | NA | 11398 | 1.00e-2 | 1.41e-2 |
Fibroblast | Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14780 | 5.00e-2 | 8.86e-3 |
Fibroblast | Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14780 | 1.00e-2 | 3.77e-2 |
Endothelial cell | Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14780 | 1.00e-3 | 2.02e-2 |
Loop of Henle | Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7381 | 1.00e-3 | 4.36e-2 |
Macrophage | Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7381 | 1.00e-3 | 4.36e-2 |
Endothelial cell (APC) | Ectopic Fat Traits | Visceral Adipose Tissue Attenutation All | MTC | Chu | 2017 | NA | 11478 | 5.00e-2 | 7.27e-5 |
Stromal cell | Ectopic Fat Traits | Visceral Adipose Tissue Attenutation All | MTC | Chu | 2017 | NA | 11478 | 5.00e-2 | 4.67e-2 |
Endothelial cell (APC) | Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 2.33e-3 |
Endothelial cell (APC) | Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14863 | 1.00e-2 | 3.62e-4 |
Fibroblast | Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 4.77e-2 |
Smooth muscle cell | Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Men | MTC | Chu | 2017 | NA | 7432 | 1.00e-2 | 2.82e-2 |
Fibroblast | Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Men | MTC | Chu | 2017 | NA | 7432 | 1.00e-3 | 2.57e-2 |
Endothelial cell | Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-3 | 4.78e-2 |
Endothelial cell (APC) | Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-3 | 4.78e-2 |
Smooth muscle cell | Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 4.22e-2 |
Stromal cell | Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 1.00e-3 | 1.49e-3 |
Loop of Henle | Ectopic Fat Traits | Visceral Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7432 | 1.00e-2 | 4.83e-2 |
Macrophage | Ectopic Fat Traits | Visceral Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7432 | 1.00e-2 | 4.83e-2 |
Endothelial cell | Estimated Glomerular Filtration Rate | Chronic Kidney Disease With Diabetes | MTC | Pattaro | 2016 | NA | 11522 | 5.00e-2 | 1.09e-2 |
Endothelial cell | Estimated Glomerular Filtration Rate | Chronic Kidney Disease With Diabetes | MTC | Pattaro | 2016 | NA | 11522 | 1.00e-2 | 1.52e-2 |
Endothelial cell | Estimated Glomerular Filtration Rate | Chronic Kidney Disease Without Diabetes | MTC | Pattaro | 2016 | NA | 118448 | 1.00e-4 | 3.24e-2 |
Endothelial cell | Estimated Glomerular Filtration Rate | Chronic Kidney Disease Without Diabetes | MTC | Pattaro | 2016 | NA | 118448 | 1.00e-5 | 2.76e-2 |
Endothelial cell | Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 5.00e-2 | 2.34e-2 |
Endothelial cell | Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 1.00e-2 | 3.84e-5 |
Loop of Henle | Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 1.00e-2 | 2.21e-2 |
Endothelial cell | Estimated Glomerular Filtration Rate | Serum Creatinine African Americans Only | MTC | Pattaro | 2016 | NA | 133413 | 5.00e-2 | 4.59e-2 |
Macrophage | Estimated Glomerular Filtration Rate | Serum Creatinine African Americans Only | MTC | Pattaro | 2016 | NA | 133413 | 5.00e-2 | 1.66e-2 |
Fibroblast | Facial Shape | Mod1 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.32e-2 |
Fibroblast | Facial Shape | Mod10 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.55e-2 |
Stromal cell | Facial Shape | Mod10 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.31e-2 |
Fibroblast | Facial Shape | Mod11 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.67e-2 |
Smooth muscle cell | Facial Shape | Mod12 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.60e-3 |
Loop of Henle | Facial Shape | Mod13 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.42e-2 |
Endothelial cell | Facial Shape | Mod14 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.28e-2 |
Smooth muscle cell | Facial Shape | Mod15 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.54e-3 |
Endothelial cell (APC) | Facial Shape | Mod17 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.43e-2 |
Endothelial cell (APC) | Facial Shape | Mod17 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 7.41e-4 |
Smooth muscle cell | Facial Shape | Mod20 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.06e-2 |
Fibroblast | Facial Shape | Mod20 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.06e-2 |
Stromal cell | Facial Shape | Mod20 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.62e-2 |
Stromal cell | Facial Shape | Mod21 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.06e-3 |
Smooth muscle cell | Facial Shape | Mod23 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.57e-2 |
Loop of Henle | Facial Shape | Mod24 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.64e-2 |
Smooth muscle cell | Facial Shape | Mod25 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.06e-3 |
Smooth muscle cell | Facial Shape | Mod25 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.61e-2 |
Smooth muscle cell | Facial Shape | Mod26 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.32e-2 |
Loop of Henle | Facial Shape | Mod27 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.71e-2 |
Endothelial cell | Facial Shape | Mod28 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.42e-2 |
Endothelial cell | Facial Shape | Mod28 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 5.99e-3 |
Endothelial cell (APC) | Facial Shape | Mod28 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.48e-2 |
Endothelial cell | Facial Shape | Mod32 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.08e-2 |
Endothelial cell (APC) | Facial Shape | Mod34 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 2.57e-2 |
Smooth muscle cell | Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.42e-3 |
Fibroblast | Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.25e-2 |
Stromal cell | Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 7.55e-3 |
Endothelial cell (APC) | Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.04e-2 |
Stromal cell | Facial Shape | Mod37 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.71e-2 |
Endothelial cell (APC) | Facial Shape | Mod39 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.31e-2 |
Fibroblast | Facial Shape | Mod4 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.26e-2 |
Stromal cell | Facial Shape | Mod4 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 9.33e-4 |
Stromal cell | Facial Shape | Mod40 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.61e-2 |
Loop of Henle | Facial Shape | Mod40 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.12e-2 |
Smooth muscle cell | Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.18e-2 |
Smooth muscle cell | Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.15e-2 |
Fibroblast | Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.12e-4 |
Stromal cell | Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.15e-2 |
Fibroblast | Facial Shape | Mod44 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.12e-2 |
Loop of Henle | Facial Shape | Mod45 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.95e-2 |
Loop of Henle | Facial Shape | Mod45 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.01e-2 |
Smooth muscle cell | Facial Shape | Mod46 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.97e-2 |
Smooth muscle cell | Facial Shape | Mod46 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 1.58e-2 |
Stromal cell | Facial Shape | Mod46 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.97e-2 |
Fibroblast | Facial Shape | Mod47 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.26e-2 |
Loop of Henle | Facial Shape | Mod47 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.26e-2 |
Fibroblast | Facial Shape | Mod49 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 9.37e-3 |
Fibroblast | Facial Shape | Mod5 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 9.59e-3 |
Smooth muscle cell | Facial Shape | Mod50 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 8.43e-3 |
Stromal cell | Facial Shape | Mod50 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.38e-2 |
Smooth muscle cell | Facial Shape | Mod51 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.58e-3 |
Endothelial cell (APC) | Facial Shape | Mod58 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.13e-2 |
Endothelial cell | Facial Shape | Mod59 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.13e-2 |
Smooth muscle cell | Facial Shape | Mod6 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.92e-2 |
Fibroblast | Facial Shape | Mod62 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 5.92e-3 |
Endothelial cell (APC) | Facial Shape | Mod8 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.90e-2 |
Endothelial cell (APC) | Facial Shape | Mod8 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.38e-2 |
Smooth muscle cell | Forced Expiratory Volume | Forced Expiratory Volume Over Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-4 | 4.78e-2 |
Stromal cell | Gestational Weight Gain | Early Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 7704 | 1.00e-3 | 5.72e-4 |
Macrophage | Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 5.00e-2 | 4.95e-2 |
Smooth muscle cell | Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 1.00e-2 | 1.92e-2 |
Endothelial cell | Gestational Weight Gain | Late Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 7681 | 5.00e-2 | 2.87e-2 |
Endothelial cell (APC) | Gestational Weight Gain | Late Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 7681 | 5.00e-2 | 4.29e-2 |
Endothelial cell (APC) | Gestational Weight Gain | Late Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 7681 | 1.00e-2 | 1.17e-2 |
Endothelial cell (APC) | Gestational Weight Gain | Late Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 7681 | 1.00e-3 | 2.57e-2 |
Endothelial cell (APC) | Gestational Weight Gain | Total Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 16434 | 1.00e-2 | 3.24e-2 |
Endothelial cell | Gestational Weight Gain | Total Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 10555 | 5.00e-2 | 3.77e-2 |
Endothelial cell | Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 4.82e-2 |
Endothelial cell | Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 3.54e-2 |
Fibroblast | Glucose Stimulated Insulin Secretion | Incremental Insulin At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 4.89e-2 |
Fibroblast | Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 1.27e-2 |
Fibroblast | Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes Corrected For BMI | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 3.32e-2 |
Smooth muscle cell | Glucose Stimulated Insulin Secretion | Insulin Sensitivity Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 3.18e-2 |
Fibroblast | Glucose Stimulated Insulin Secretion | Insulin Sensitivity Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 4.86e-2 |
Fibroblast | Glucose Stimulated Insulin Secretion | Insulin Sensitivity Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 2.72e-2 |
Stromal cell | Glucose Stimulated Insulin Secretion | Insulin Sensitivity Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 1.24e-2 |
Stromal cell | Glycemic Traits BMI Corrected | Fasting Glucose Interaction With BMI | MTC | Manning | 2012 | NA | 58074 | 1.00e-2 | 3.97e-2 |
Endothelial cell | Glycemic Traits BMI Corrected | Fasting Insulin Interaction With BMI | MTC | Manning | 2012 | NA | 51750 | 5.00e-2 | 3.30e-2 |
Stromal cell | Glycemic Traits | Fasting Insulin | ETC | Dupuis | 2010 | NA | 38238 | 1.00e-3 | 2.46e-3 |
Loop of Henle | Glycemic Traits | HOMA B | MTC | Dupuis | 2010 | NA | 36466 | 5.00e-2 | 1.30e-2 |
Endothelial cell (APC) | Glycemic Traits | HOMA B | MTC | Dupuis | 2010 | NA | 36466 | 1.00e-2 | 1.31e-2 |
Endothelial cell (APC) | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-2 | 3.52e-2 |
Endothelial cell | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-3 | 2.14e-2 |
Endothelial cell | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-2 | 1.37e-2 |
Endothelial cell (APC) | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-2 | 2.06e-2 |
Endothelial cell (APC) | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-3 | 8.76e-3 |
Endothelial cell (APC) | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-5 | 3.29e-2 |
Macrophage | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-3 | 4.03e-2 |
Endothelial cell | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 5.00e-2 | 3.46e-4 |
Endothelial cell | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-2 | 6.01e-3 |
Endothelial cell | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-4 | 3.08e-2 |
Endothelial cell | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-5 | 4.87e-3 |
Macrophage | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 5.00e-2 | 4.19e-2 |
Macrophage | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-2 | 3.95e-2 |
Macrophage | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-3 | 2.02e-2 |
Macrophage | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-4 | 1.00e-2 |
Macrophage | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-5 | 4.87e-3 |
Endothelial cell (APC) | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-4 | 3.08e-2 |
Endothelial cell (APC) | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-5 | 4.87e-3 |
Endothelial cell | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 5.00e-2 | 1.65e-4 |
Endothelial cell | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-2 | 1.70e-3 |
Endothelial cell | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-3 | 2.43e-2 |
Endothelial cell | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-4 | 4.95e-4 |
Endothelial cell | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-5 | 9.75e-5 |
Endothelial cell (APC) | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 5.00e-2 | 4.58e-2 |
Endothelial cell (APC) | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-2 | 7.44e-3 |
Endothelial cell (APC) | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-3 | 4.07e-2 |
Endothelial cell (APC) | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-4 | 4.30e-2 |
Endothelial cell (APC) | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-5 | 1.30e-2 |
Macrophage | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 5.00e-2 | 4.86e-3 |
Macrophage | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-2 | 5.73e-4 |
Macrophage | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-3 | 4.11e-3 |
Macrophage | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-4 | 2.68e-3 |
Macrophage | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-5 | 8.35e-4 |
Endothelial cell | Insulin Secretion | Acute Insulin Response Adjusted For BMI And Insulin Sensitivity | MTC | Wood | 2017 | NA | 2087 | 1.00e-2 | 3.70e-2 |
Loop of Henle | Insulin Secretion | Acute Insulin Response Adjusted For BMI And Insulin Sensitivity | MTC | Wood | 2017 | NA | 2087 | 1.00e-2 | 8.43e-3 |
Loop of Henle | Insulin Secretion | Acute Insulin Response Adjusted For Insulin Sensitivity | MTC | Wood | 2017 | NA | 2087 | 5.00e-2 | 2.56e-2 |
Loop of Henle | Insulin Secretion | Acute Insulin Response Adjusted For Insulin Sensitivity | MTC | Wood | 2017 | NA | 2087 | 1.00e-2 | 2.56e-2 |
Endothelial cell | Insulin Secretion | Acute Insulin Response Adjusted For Insulin Sensitivity | MTC | Wood | 2017 | NA | 2087 | 1.00e-2 | 2.17e-3 |
Fibroblast | Insulin Secretion | Insulin Secretion Rate Adjusted For BMI | MTC | Wood | 2017 | NA | 527 | 1.00e-3 | 2.97e-2 |
Smooth muscle cell | Insulin Secretion | Peak Insulin Response | MTC | Wood | 2017 | NA | 2159 | 1.00e-2 | 3.86e-2 |
Loop of Henle | Insulin Secretion | Peak Insulin Response | MTC | Wood | 2017 | NA | 2159 | 1.00e-2 | 1.92e-2 |
Loop of Henle | Insulin Secretion | Peak Insulin Response Adjusted For BMI And Insulin Sensitivity | MTC | Wood | 2017 | NA | 2159 | 1.00e-2 | 4.96e-2 |
Loop of Henle | Insulin Secretion | Peak Insulin Response Adjusted For BMI And Insulin Sensitivity | MTC | Wood | 2017 | NA | 2159 | 1.00e-3 | 2.89e-2 |
Loop of Henle | Insulin Secretion | Peak Insulin Response Adjusted For Insulin Sensitivity | MTC | Wood | 2017 | NA | 2159 | 1.00e-2 | 3.05e-2 |
Loop of Henle | Insulin Secretion | Peak Insulin Response Adjusted For Insulin Sensitivity | MTC | Wood | 2017 | NA | 2159 | 1.00e-3 | 2.02e-2 |
Smooth muscle cell | Insulin Sensitivity Index | Model 1 | MTC | Walford | 2016 | NA | 16753 | 1.00e-2 | 2.79e-2 |
Smooth muscle cell | Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 2.69e-2 |
Smooth muscle cell | Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 1.00e-2 | 2.92e-2 |
Smooth muscle cell | Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 1.00e-3 | 1.04e-2 |
Stromal cell | Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 3.94e-2 |
Stromal cell | Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 1.00e-3 | 3.44e-2 |
Fibroblast | Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 1.00e-2 | 3.11e-2 |
Endothelial cell | Intracerebral Hemorrhage | Lobar ICH | MTC | Woo | 2014 | 664 | 1481 | 5.00e-2 | 2.35e-2 |
Fibroblast | Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 5.00e-2 | 2.84e-2 |
Endothelial cell | Ischaemic Stroke | All Stroke | MTC | Traylor | 2012 | 10210 | 12285 | 1.00e-2 | 2.01e-2 |
Endothelial cell | Ischaemic Stroke | All Stroke | MTC | Traylor | 2012 | 10210 | 12285 | 1.00e-3 | 2.29e-2 |
Endothelial cell | Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 5.00e-2 | 1.63e-2 |
Stromal cell | Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 5.00e-2 | 6.08e-3 |
Stromal cell | Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 1.00e-2 | 2.81e-3 |
Loop of Henle | Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 5.00e-2 | 3.93e-2 |
Stromal cell | Kidney Function | eGFR Decline With Chronic Kidney Disease | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 1.36e-2 |
Endothelial cell | Kidney Function | Rapid Decline Without Chronic Kidney Disease | MTC | Gorski | 2015 | NA | 45530 | 1.00e-2 | 4.51e-2 |
Loop of Henle | Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-3 | 4.79e-2 |
Endothelial cell | Kidney Function | Serum Creatinine | MTC | Kottgen | 2010 | NA | 67093 | 5.00e-2 | 2.15e-2 |
Endothelial cell | Kidney Function | Serum Creatinine | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-2 | 2.71e-2 |
Endothelial cell | Kidney Function | Serum Creatinine | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-3 | 4.69e-2 |
Endothelial cell | Kidney Function | Serum Creatinine | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-4 | 4.29e-2 |
Smooth muscle cell | Kidney Function | Serum Creatinine | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-4 | 4.29e-2 |
Smooth muscle cell | Kidney Function | Serum Creatinine | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-5 | 2.89e-2 |
Endothelial cell | Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 5.00e-2 | 1.36e-3 |
Endothelial cell | Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-2 | 2.55e-2 |
Endothelial cell | Lean Body Mass | Appendicular Lean Mass | MTC | Zillikens | 2017 | NA | 28330 | 1.00e-2 | 4.49e-2 |
Fibroblast | Lean Body Mass | Whole Body Lean Mass | MTC | Zillikens | 2017 | NA | 38292 | 1.00e-2 | 4.29e-2 |
Stromal cell | Lean Body Mass | Whole Body Lean Mass | MTC | Zillikens | 2017 | NA | 38292 | 1.00e-2 | 7.28e-3 |
Loop of Henle | Leptin | Leptin Adjusted For BMI | MTC | Kilpelainen | 2016 | NA | 32161 | 1.00e-2 | 2.75e-2 |
Loop of Henle | Leptin | Leptin Not Adjusted For BMI | ETC | Kilpelainen | 2016 | NA | 32161 | 1.00e-2 | 3.39e-2 |
Loop of Henle | Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Activity | MTC | Suchindran | 2010 | NA | 6668 | 5.00e-2 | 3.93e-2 |
Endothelial cell | Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Activity | MTC | Suchindran | 2010 | NA | 6668 | 1.00e-3 | 1.78e-2 |
Endothelial cell (APC) | Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Mass | MTC | Suchindran | 2010 | NA | 6668 | 1.00e-2 | 2.76e-2 |
Fibroblast | Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Mass | MTC | Suchindran | 2010 | NA | 6668 | 1.00e-2 | 2.76e-2 |
Endothelial cell | Lipoprotein Concentrations | High Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 1.62e-2 |
Endothelial cell (APC) | Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 6.18e-3 |
Endothelial cell (APC) | Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-2 | 2.67e-2 |
Endothelial cell (APC) | Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-3 | 1.67e-2 |
Endothelial cell (APC) | Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-4 | 1.35e-2 |
Endothelial cell (APC) | Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-5 | 1.88e-2 |
Macrophage | Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-2 | 2.67e-2 |
Endothelial cell | Longevity | Age 85 Or Greater | MTC | Deelen | 2014 | 7729 | 16121 | 1.00e-2 | 3.10e-2 |
Stromal cell | Longevity | Age 90 Or Greater | MTC | Deelen | 2014 | 5406 | 15112 | 1.00e-2 | 3.75e-2 |
Endothelial cell | Lymphocyte Subsets | CD19 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 1.73e-2 |
Endothelial cell | Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 3.49e-3 |
Endothelial cell (APC) | Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 1.35e-6 |
Endothelial cell (APC) | Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 1.68e-6 |
Endothelial cell | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 4.69e-3 |
Endothelial cell | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 6.68e-4 |
Endothelial cell | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 9.41e-7 |
Endothelial cell | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 1.00e-4 |
Endothelial cell | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 2.73e-3 |
Endothelial cell (APC) | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 4.69e-3 |
Endothelial cell (APC) | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 1.30e-5 |
Endothelial cell (APC) | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 4.53e-6 |
Endothelial cell (APC) | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 7.85e-8 |
Endothelial cell (APC) | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 3.65e-6 |
Macrophage | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 2.79e-3 |
Macrophage | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 7.74e-3 |
Macrophage | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 8.39e-5 |
Macrophage | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 4.64e-4 |
Macrophage | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 6.26e-4 |
Endothelial cell | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 3.74e-4 |
Endothelial cell | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 1.25e-2 |
Endothelial cell | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 2.49e-2 |
Smooth muscle cell | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 1.73e-2 |
Endothelial cell (APC) | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 1.96e-4 |
Endothelial cell (APC) | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 4.24e-4 |
Endothelial cell (APC) | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 1.18e-4 |
Endothelial cell (APC) | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 1.78e-2 |
Macrophage | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 7.85e-3 |
Macrophage | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 1.78e-2 |
Endothelial cell | Lymphocyte Subsets | CD56 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 3.44e-2 |
Fibroblast | Lymphocyte Subsets | CD56 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 8.91e-3 |
Fibroblast | Lymphocyte Subsets | CD56 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 7.79e-4 |
Loop of Henle | Lymphocyte Subsets | CD56 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 1.43e-2 |
Loop of Henle | Lymphocyte Subsets | CD56 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 4.89e-2 |
Macrophage | Lymphocyte Subsets | CD56 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 8.91e-3 |
Macrophage | Lymphocyte Subsets | CD56 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 4.95e-3 |
Stromal cell | Lymphocyte Subsets | CD56 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 4.89e-2 |
Endothelial cell (APC) | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 7.67e-5 |
Endothelial cell (APC) | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 4.76e-6 |
Endothelial cell (APC) | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 1.72e-5 |
Endothelial cell (APC) | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 8.78e-6 |
Endothelial cell (APC) | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 1.76e-6 |
Endothelial cell | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 3.32e-2 |
Endothelial cell | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 4.51e-3 |
Endothelial cell | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 1.80e-3 |
Macrophage | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 1.22e-2 |
Macrophage | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 4.51e-3 |
Macrophage | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 1.80e-3 |
Smooth muscle cell | TB LM | Total body lean mass | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 4.62e-3 |
Stromal cell | TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 3.00e-2 |
Loop of Henle | TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 4.41e-2 |
Loop of Henle | TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 1.00e-3 | 4.42e-2 |
Fibroblast | New Onset Diabetes | New Onset Diabetes After Drugs, European American | MTC | Chang | 2018 | 138 | 414 | 5.00e-2 | 3.11e-2 |
Fibroblast | New Onset Diabetes | New Onset Diabetes After Drugs, European American | MTC | Chang | 2018 | 138 | 414 | 1.00e-2 | 6.35e-3 |
Stromal cell | New Onset Diabetes | New Onset Diabetes After Drugs, European American | MTC | Chang | 2018 | 138 | 414 | 5.00e-2 | 3.29e-3 |
Stromal cell | New Onset Diabetes | New Onset Diabetes After Drugs, European American | MTC | Chang | 2018 | 138 | 414 | 1.00e-2 | 1.69e-3 |
Loop of Henle | New Onset Diabetes | New Onset Diabetes After Drugs, European American | MTC | Chang | 2018 | 138 | 414 | 5.00e-2 | 3.11e-2 |
Smooth muscle cell | New Onset Diabetes | New Onset Diabetes After Drugs, European American | MTC | Chang | 2018 | 138 | 414 | 1.00e-2 | 2.09e-2 |
Endothelial cell | Personality Big5 | Agreeableness | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 1.28e-2 |
Endothelial cell (APC) | Personality Big5 | Agreeableness | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 1.28e-2 |
Endothelial cell (APC) | Personality Big5 | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 4.94e-2 |
Endothelial cell (APC) | Personality Big5 | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 4.78e-2 |
Loop of Henle | Personality Big5 | Openness To Experience | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 5.12e-3 |
Fibroblast | Pubertal Anthropometrics | Height 10 Year Females | MTC | Cousminer | 2013 | NA | 14040 | 1.00e-2 | 2.14e-2 |
Stromal cell | Pubertal Anthropometrics | Height 10 Year Females And 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 5.00e-2 | 4.90e-2 |
Stromal cell | Pubertal Anthropometrics | Height 10 Year Females And 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 1.00e-2 | 6.86e-3 |
Fibroblast | Pubertal Anthropometrics | Height 10 Year Females And 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 1.00e-2 | 6.86e-3 |
Stromal cell | Pubertal Anthropometrics | Height 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 1.00e-2 | 2.81e-2 |
Smooth muscle cell | Pubertal Anthropometrics | Late Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-2 | 4.14e-3 |
Smooth muscle cell | Pubertal Anthropometrics | Late Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-3 | 3.24e-3 |
Endothelial cell (APC) | Pubertal Anthropometrics | Total Pubertal Height Increase | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 4.24e-3 |
Endothelial cell (APC) | Pubertal Anthropometrics | Total Pubertal Height Increase | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-2 | 6.10e-4 |
Endothelial cell (APC) | Pubertal Anthropometrics | Total Pubertal Height Increase Females | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-2 | 4.44e-2 |
Smooth muscle cell | Pubertal Anthropometrics | Total Pubertal Height Increase Females | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-3 | 2.29e-2 |
Endothelial cell (APC) | Pubertal Anthropometrics | Total Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 1.62e-3 |
Endothelial cell (APC) | Pubertal Anthropometrics | Total Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-2 | 3.54e-2 |
Fibroblast | Reproductive Behavior | Age First Birth Male | MTC | Barban | 2016 | NA | 48408 | 1.00e-2 | 4.98e-2 |
Fibroblast | Reproductive Behavior | Age First Birth Male | MTC | Barban | 2016 | NA | 48408 | 1.00e-3 | 4.51e-3 |
Fibroblast | Reproductive Behavior | Age First Birth Male | MTC | Barban | 2016 | NA | 48408 | 1.00e-4 | 1.88e-2 |
Endothelial cell | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 5.00e-2 | 3.05e-2 |
Endothelial cell | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-2 | 3.28e-2 |
Endothelial cell | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-3 | 7.01e-5 |
Endothelial cell | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-4 | 3.73e-5 |
Endothelial cell | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-5 | 5.98e-6 |
Endothelial cell (APC) | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 5.00e-2 | 5.34e-3 |
Endothelial cell (APC) | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-2 | 2.41e-5 |
Endothelial cell (APC) | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-3 | 1.74e-3 |
Endothelial cell (APC) | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-4 | 1.59e-3 |
Endothelial cell (APC) | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-5 | 1.78e-4 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 5.00e-2 | 2.22e-2 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-2 | 6.18e-4 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-3 | 7.01e-5 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-4 | 2.68e-4 |
Macrophage | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-5 | 6.05e-5 |
Endothelial cell (APC) | Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 5.00e-2 | 2.98e-2 |
Fibroblast | Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 5.00e-2 | 2.98e-2 |
Fibroblast | Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 1.00e-3 | 2.58e-2 |
Smooth muscle cell | Sleep Duration | Average Sleep Duration | MTC | Jones | 2016 | NA | 127573 | 1.00e-2 | 1.11e-2 |
Smooth muscle cell | Sleep Duration | Average Sleep Duration | MTC | Jones | 2016 | NA | 127573 | 1.00e-3 | 3.81e-3 |
Endothelial cell | Circadian Rhythm | Sleep Chronotype | MTC | Jones | 2016 | NA | 127898 | 1.00e-5 | 4.90e-2 |
Endothelial cell | Stroke (ischemic) | Large Artery Stroke | MTC | Traylor | 2017 | 2167 | 62004 | 5.00e-2 | 2.18e-3 |
Endothelial cell | Stroke (ischemic) | Large Artery Stroke | MTC | Traylor | 2017 | 2167 | 62004 | 1.00e-3 | 4.90e-2 |
Smooth muscle cell | Stroke (ischemic) | Large Artery Stroke | MTC | Traylor | 2017 | 2167 | 62004 | 5.00e-2 | 2.63e-2 |
Endothelial cell | Stroke (ischemic) | Small Vessel Stroke | MTC | Traylor | 2017 | 1894 | 62004 | 1.00e-2 | 1.31e-2 |
Fibroblast | Smoking | Cigarettes Per Day | ETC | Furberg | 2010 | NA | 38181 | 1.00e-2 | 3.26e-2 |
Endothelial cell | Smoking | Cigarettes Per Day | ETC | Furberg | 2010 | NA | 38181 | 1.00e-3 | 7.11e-3 |
Endothelial cell | Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 5.00e-2 | 3.43e-2 |
Endothelial cell (APC) | Smoking | Log Age Onset Smoking | MTC | Furberg | 2010 | NA | 22438 | 5.00e-2 | 2.13e-2 |
Smooth muscle cell | Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 1.07e-2 |
Stromal cell | Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 2.46e-3 |
Endothelial cell (APC) | Statin Efficacy | Delta LDL | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 7.91e-3 |
Endothelial cell (APC) | Statin Efficacy | Delta LDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 1.73e-2 |
Loop of Henle | Statin Efficacy | Delta LDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 1.73e-2 |
Endothelial cell (APC) | Statin Efficacy | Delta TC | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 3.26e-2 |
Fibroblast | Statin Efficacy | Delta TC | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 1.36e-2 |
Fibroblast | Statin Efficacy | Delta TC | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 1.66e-2 |
Macrophage | Statin Efficacy | Delta TC | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 3.33e-2 |
Smooth muscle cell | Statin Efficacy | Delta TC With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 9.05e-3 |
Smooth muscle cell | Statin Efficacy | Delta TC With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 2.58e-2 |
Macrophage | Statin Efficacy | Delta TC With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 2.00e-2 |
Smooth muscle cell | Statin Efficacy | Delta TG | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 1.09e-2 |
Macrophage | Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 1.00e-3 | 3.40e-2 |
Endothelial cell | Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 5.00e-2 | 3.37e-2 |
Stromal cell | Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-5 | 2.01e-2 |
Endothelial cell | Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 5.00e-2 | 3.83e-2 |
Endothelial cell | Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-2 | 4.28e-2 |
Loop of Henle | Waist Format 1 | Hip Circumference European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 4.02e-2 |
Fibroblast | Waist Format 1 | Waist Circumference Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-3 | 2.60e-2 |
Loop of Henle | Waist Format 1 | Waist Circumference Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-3 | 2.60e-2 |
Endothelial cell | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 5.97e-3 |
Endothelial cell | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 7.07e-3 |
Endothelial cell (APC) | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 4.75e-2 |
Endothelial cell (APC) | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 1.37e-2 |
Endothelial cell (APC) | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 2.02e-3 |
Endothelial cell (APC) | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-4 | 8.93e-3 |
Endothelial cell (APC) | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 1.00e-4 |
Stromal cell | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 6.82e-4 |
Stromal cell | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 2.19e-2 |
Loop of Henle | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 2.28e-2 |
Macrophage | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 2.28e-2 |
Endothelial cell (APC) | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 2.36e-2 |
Endothelial cell (APC) | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-5 | 4.42e-2 |
Stromal cell | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 3.27e-2 |
Stromal cell | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 1.20e-2 |
Endothelial cell | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 1.11e-2 |
Endothelial cell | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 3.40e-2 |
Endothelial cell (APC) | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 1.19e-3 |
Endothelial cell (APC) | Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 9.52e-3 |
Endothelial cell (APC) | Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 1.77e-2 |
Endothelial cell (APC) | Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 2.67e-3 |
Endothelial cell (APC) | Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-4 | 2.55e-2 |
Fibroblast | Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 4.55e-2 |
Stromal cell | Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 3.75e-4 |
Stromal cell | Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 2.64e-3 |
Loop of Henle | Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 3.10e-2 |
Endothelial cell (APC) | Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 1.74e-2 |
Endothelial cell (APC) | Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 4.23e-2 |
Endothelial cell (APC) | Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-4 | 3.56e-2 |
Stromal cell | Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 5.71e-3 |
Loop of Henle | Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 4.59e-2 |
Endothelial cell (APC) | Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 3.03e-3 |
Endothelial cell (APC) | Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-2 | 5.86e-3 |
Stromal cell | Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 3.05e-2 |
Stromal cell | Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 3.18e-2 |
Loop of Henle | Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-3 | 7.07e-3 |
Endothelial cell (APC) | Waist Format 2 | Waist Hip Ratio European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 4.16e-2 |
Endothelial cell | Waist Format 2 | Waist Hip Ratio European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 4.36e-2 |
Endothelial cell (APC) | Waist Format 2 | Waist Hip Ratio Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 4.47e-2 |
Endothelial cell (APC) | Waist Format 2 | Waist Hip Ratio Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 3.86e-2 |
Macrophage | Waist Format 2 | Waist Hip Ratio Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 3.86e-2 |
Stromal cell | BIP | Bipolar disorder | ETC | Stahl | 2018 | 20352 | 31358 | 1.00e-5 | 2.68e-2 |
Endothelial cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 5.00e-2 | 1.78e-5 |
Endothelial cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-2 | 6.79e-4 |
Endothelial cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-3 | 2.83e-4 |
Endothelial cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-4 | 6.62e-4 |
Endothelial cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-5 | 1.54e-4 |
Endothelial cell (APC) | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 5.00e-2 | 2.36e-3 |
Endothelial cell (APC) | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-2 | 2.17e-3 |
Endothelial cell (APC) | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-3 | 4.90e-5 |
Endothelial cell (APC) | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-4 | 1.01e-5 |
Endothelial cell (APC) | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-5 | 5.02e-5 |
Macrophage | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 5.00e-2 | 9.99e-4 |
Macrophage | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-2 | 3.66e-4 |
Macrophage | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-3 | 6.41e-4 |
Macrophage | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-4 | 1.65e-3 |
Macrophage | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-5 | 4.48e-4 |
Loop of Henle | PAN | Pancreatic Cancer | ETC | Amundadottir | 2009 | 1771 | 1805 | 1.00e-2 | 1.57e-2 |
Macrophage | PAN | Pancreatic Cancer | ETC | Amundadottir | 2009 | 1771 | 1805 | 1.00e-2 | 3.24e-2 |
Macrophage | PAN | Pancreatic Cancer | ETC | Amundadottir | 2009 | 1771 | 1805 | 1.00e-3 | 2.24e-3 |
Endothelial cell (APC) | HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 5.00e-2 | 1.33e-3 |
Endothelial cell (APC) | HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-2 | 4.11e-5 |
Endothelial cell (APC) | HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-3 | 1.48e-3 |
Endothelial cell (APC) | HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-4 | 1.47e-2 |
Endothelial cell (APC) | HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-5 | 1.10e-3 |
Endothelial cell (APC) | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-2 | 1.22e-2 |
Endothelial cell (APC) | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-3 | 8.91e-3 |
Endothelial cell (APC) | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-4 | 2.14e-2 |
Endothelial cell | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 5.00e-2 | 2.75e-2 |
Endothelial cell | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-2 | 1.83e-3 |
Endothelial cell | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-3 | 2.08e-4 |
Endothelial cell | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-4 | 1.40e-6 |
Endothelial cell | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-5 | 7.78e-7 |
Endothelial cell (APC) | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 5.00e-2 | 4.71e-3 |
Endothelial cell (APC) | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-2 | 1.02e-3 |
Endothelial cell (APC) | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-3 | 2.28e-3 |
Endothelial cell (APC) | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-4 | 5.53e-5 |
Endothelial cell (APC) | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-5 | 5.41e-5 |
Macrophage | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 5.00e-2 | 2.10e-3 |
Macrophage | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-2 | 5.51e-4 |
Macrophage | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-3 | 8.67e-5 |
Macrophage | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-4 | 3.37e-3 |
Macrophage | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-5 | 6.44e-4 |
Endothelial cell (APC) | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 5.00e-2 | 5.79e-5 |
Endothelial cell (APC) | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-2 | 1.17e-5 |
Endothelial cell (APC) | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-3 | 4.02e-4 |
Endothelial cell (APC) | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-4 | 1.46e-5 |
Endothelial cell (APC) | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-5 | 5.38e-6 |
Macrophage | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 5.00e-2 | 1.22e-2 |
Macrophage | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-2 | 1.69e-3 |
Macrophage | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-3 | 2.95e-5 |
Macrophage | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-4 | 1.50e-6 |
Macrophage | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-5 | 5.38e-6 |
Endothelial cell | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-3 | 3.87e-3 |
Endothelial cell | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-4 | 3.14e-4 |
Endothelial cell | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-5 | 4.58e-4 |
Endothelial cell | RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 5.00e-2 | 2.74e-3 |
Endothelial cell | RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-2 | 6.52e-4 |
Endothelial cell | RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-3 | 2.09e-2 |
Endothelial cell | RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-4 | 5.48e-3 |
Endothelial cell | RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-5 | 1.09e-3 |
Endothelial cell (APC) | RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-2 | 2.09e-2 |
Endothelial cell | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 5.00e-2 | 1.77e-3 |
Endothelial cell | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-2 | 4.12e-4 |
Endothelial cell | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-3 | 8.71e-4 |
Endothelial cell | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-4 | 1.30e-4 |
Endothelial cell | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-5 | 4.24e-4 |
Macrophage | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 5.00e-2 | 1.07e-2 |
Macrophage | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-2 | 1.18e-2 |
Macrophage | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-3 | 1.70e-3 |
Macrophage | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-4 | 3.48e-3 |
Macrophage | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-5 | 2.56e-3 |
Endothelial cell (APC) | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-2 | 3.70e-2 |
Endothelial cell (APC) | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-3 | 1.79e-2 |
Endothelial cell (APC) | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-4 | 1.63e-3 |
Endothelial cell (APC) | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-5 | 4.24e-4 |
Endothelial cell | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 5.00e-2 | 9.04e-4 |
Endothelial cell | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-2 | 2.44e-5 |
Endothelial cell | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-3 | 4.39e-7 |
Endothelial cell | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-4 | 3.25e-8 |
Endothelial cell | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-5 | 2.22e-6 |
Endothelial cell (APC) | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 5.00e-2 | 9.04e-4 |
Endothelial cell (APC) | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-2 | 1.93e-6 |
Endothelial cell (APC) | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-3 | 1.84e-7 |
Endothelial cell (APC) | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-4 | 1.14e-5 |
Endothelial cell (APC) | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-5 | 2.22e-6 |
Macrophage | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 5.00e-2 | 8.01e-3 |
Macrophage | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-2 | 6.51e-3 |
Macrophage | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-3 | 1.98e-4 |
Macrophage | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-4 | 2.61e-3 |
Macrophage | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-5 | 2.89e-3 |
Endothelial cell | CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 5.00e-2 | 4.45e-3 |
Stromal cell | CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-4 | 3.75e-2 |
Endothelial cell (APC) | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 5.00e-2 | 2.07e-2 |
Endothelial cell (APC) | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-2 | 2.42e-3 |
Endothelial cell (APC) | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-3 | 4.36e-2 |
Macrophage | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-4 | 2.94e-2 |
Fibroblast | Ambidextrousness | Ambidextrousness | ETC | Kovel | 2019 | 5324 | 325713 | 5.00e-2 | 3.79e-2 |
Smooth muscle cell | Ambidextrousness | Ambidextrousness | ETC | Kovel | 2019 | 5324 | 325713 | 1.00e-2 | 3.05e-2 |
Endothelial cell (APC) | Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 1.00e-2 | 2.88e-2 |
Fibroblast | Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 1.00e-2 | 4.61e-2 |
Stromal cell | Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 1.00e-2 | 2.88e-2 |
Endothelial cell | Parkinsons | Parkinsons disease, age of onset | ETC | Blauwendraat | 2019 | NA | 17996 | 5.00e-2 | 5.91e-3 |
Smooth muscle cell | Active | Time to most active 10 hours | ETC | Jones | 2019 | NA | 85670 | 1.00e-2 | 5.49e-3 |
Endothelial cell (APC) | Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 3.72e-2 |
Fibroblast | Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 1.82e-2 |
Stromal cell | Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 1.84e-4 |
Macrophage | Sleep | Sleep time to midpoint | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 1.67e-2 |
Macrophage | Sleep | Sleep time to midpoint | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 3.10e-2 |
Stromal cell | Sleep | Sleep time to midpoint | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 3.10e-2 |
Endothelial cell | Sleep | Sleep time to least active 5 hours | ETC | Jones | 2019 | NA | 85205 | 1.00e-3 | 1.66e-2 |
Endothelial cell | Sleep | Sleep time to least active 5 hours | ETC | Jones | 2019 | NA | 85205 | 1.00e-4 | 2.49e-2 |
Stromal cell | Sleep | Diurnal inactivity | ETC | Jones | 2019 | NA | 84757 | 1.00e-3 | 4.69e-2 |
Endothelial cell (APC) | Facial attractiveness | Facial attractiveness of males, male raters | ETC | Hu | 2019 | NA | 1792 | 5.00e-2 | 8.14e-3 |
Endothelial cell (APC) | Facial attractiveness | Facial attractiveness of females, female raters | ETC | Hu | 2019 | NA | 2062 | 1.00e-2 | 3.58e-2 |
Fibroblast | Facial attractiveness | Facial attractiveness of females, female raters | ETC | Hu | 2019 | NA | 2062 | 1.00e-2 | 2.42e-3 |
Endothelial cell | Facial attractiveness | Facial attractiveness of males, female raters | ETC | Hu | 2019 | NA | 1792 | 5.00e-2 | 3.52e-2 |
Endothelial cell | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 5.00e-2 | 3.52e-2 |
Endothelial cell | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-2 | 1.12e-2 |
Endothelial cell | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-3 | 4.57e-3 |
Endothelial cell | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-4 | 1.13e-2 |
Endothelial cell | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-5 | 2.22e-3 |
Endothelial cell (APC) | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 5.00e-2 | 2.06e-4 |
Endothelial cell (APC) | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-2 | 7.05e-5 |
Endothelial cell (APC) | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-3 | 3.25e-4 |
Endothelial cell (APC) | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-4 | 2.07e-4 |
Endothelial cell (APC) | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-5 | 2.94e-4 |
Macrophage | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-2 | 2.44e-2 |
Macrophage | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-4 | 2.18e-2 |
Macrophage | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-5 | 5.56e-3 |
Endothelial cell | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 5.00e-2 | 9.59e-3 |
Endothelial cell | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-2 | 1.79e-3 |
Endothelial cell | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-3 | 3.57e-4 |
Endothelial cell | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-4 | 1.54e-2 |
Endothelial cell | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-5 | 3.20e-3 |
Endothelial cell (APC) | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 5.00e-2 | 3.90e-6 |
Endothelial cell (APC) | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-2 | 9.67e-5 |
Endothelial cell (APC) | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-3 | 3.05e-7 |
Endothelial cell (APC) | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-4 | 3.22e-8 |
Endothelial cell (APC) | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-5 | 5.84e-7 |
Macrophage | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 5.00e-2 | 2.98e-2 |
Macrophage | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-2 | 1.88e-2 |
Macrophage | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-3 | 2.10e-2 |
Macrophage | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-5 | 6.21e-3 |
Fibroblast | Neuroticism | Worry-vulnerability-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-4 | 3.62e-2 |
Fibroblast | Neuroticism | Anxiety-tension-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-4 | 3.62e-2 |
Endothelial cell (APC) | Na/K ratio | Urinary sodium to potassium ratio | ETC | Zanetti | 2019 | NA | 108942 | 5.00e-2 | 2.20e-3 |
Endothelial cell (APC) | Na/K ratio | Urinary sodium to potassium ratio | ETC | Zanetti | 2019 | NA | 108942 | 1.00e-2 | 3.56e-4 |
Endothelial cell (APC) | Na/K ratio | Urinary sodium to potassium ratio | ETC | Zanetti | 2019 | NA | 108942 | 1.00e-3 | 1.78e-2 |
Endothelial cell (APC) | K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-3 | 2.23e-2 |
Endothelial cell (APC) | K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-4 | 3.60e-3 |
Endothelial cell (APC) | K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-5 | 2.82e-2 |
Fibroblast | K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-4 | 2.76e-2 |
Fibroblast | K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-5 | 1.30e-2 |
Endothelial cell (APC) | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 5.00e-2 | 1.05e-2 |
Endothelial cell (APC) | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-2 | 2.41e-2 |
Endothelial cell (APC) | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-3 | 2.46e-2 |
Endothelial cell (APC) | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-4 | 2.90e-5 |
Endothelial cell (APC) | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-5 | 6.25e-6 |
Fibroblast | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-3 | 6.10e-4 |
Fibroblast | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-4 | 3.77e-3 |
Fibroblast | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-5 | 2.77e-3 |
Stromal cell | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-3 | 2.46e-2 |
Stromal cell | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-4 | 2.60e-2 |
Endothelial cell | MI/CF | Meconium ileus in cystic fibrosis | ETC | Gong | 2019 | 1115 | 5655 | 5.00e-2 | 1.51e-2 |
Endothelial cell | MI/CF | Meconium ileus in cystic fibrosis | ETC | Gong | 2019 | 1115 | 5655 | 1.00e-2 | 1.41e-2 |
Loop of Henle | MI/CF | Meconium ileus in cystic fibrosis | ETC | Gong | 2019 | 1115 | 5655 | 5.00e-2 | 1.51e-2 |
Endothelial cell | Obesity | Obesity, extreme obese children vs control adult | ETC | McKay | 2019 | 1456 | 6460 | 5.00e-2 | 1.57e-2 |
Endothelial cell | Obesity | Obesity, extreme obese children vs control adult | ETC | McKay | 2019 | 1456 | 6460 | 1.00e-2 | 2.01e-2 |
Fibroblast | Obesity | Obesity, extreme obese children vs control adult | ETC | McKay | 2019 | 1456 | 6460 | 5.00e-2 | 2.35e-2 |
Fibroblast | Obesity | Obesity, extreme obese children vs control adult | ETC | McKay | 2019 | 1456 | 6460 | 1.00e-3 | 5.68e-3 |
Endothelial cell (APC) | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 5.00e-2 | 4.49e-2 |
Endothelial cell (APC) | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-2 | 3.11e-2 |
Endothelial cell (APC) | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-3 | 3.14e-4 |
Endothelial cell (APC) | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-4 | 1.55e-4 |
Endothelial cell (APC) | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-5 | 1.52e-3 |
Macrophage | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 5.00e-2 | 2.26e-2 |
Macrophage | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-2 | 3.29e-3 |
Macrophage | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-3 | 2.32e-2 |
Macrophage | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-4 | 1.66e-3 |
Macrophage | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-5 | 3.87e-4 |
Endothelial cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-2 | 1.09e-2 |
Endothelial cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-3 | 4.96e-3 |
Endothelial cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-4 | 4.81e-3 |
Endothelial cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-5 | 1.66e-2 |
Endothelial cell (APC) | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 5.00e-2 | 1.10e-2 |
Endothelial cell (APC) | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-2 | 1.27e-3 |
Endothelial cell (APC) | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-3 | 8.59e-4 |
Endothelial cell (APC) | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-4 | 1.00e-4 |
Endothelial cell (APC) | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-5 | 5.89e-6 |
Endothelial cell | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-3 | 2.67e-4 |
Endothelial cell | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-4 | 4.64e-4 |
Endothelial cell | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-5 | 5.06e-3 |
Fibroblast | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-3 | 4.13e-2 |
Macrophage | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-3 | 7.06e-3 |
Macrophage | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-4 | 2.28e-2 |
Macrophage | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-5 | 1.92e-2 |
Stromal cell | Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 1.06e-3 |
Stromal cell | Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 1.13e-4 |
Stromal cell | Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-3 | 2.54e-2 |
Stromal cell | Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-4 | 5.84e-3 |
Stromal cell | Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-5 | 1.74e-2 |
Endothelial cell | Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-3 | 6.38e-3 |
Fibroblast | Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 2.43e-2 |
Stromal cell | Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 1.34e-3 |
Stromal cell | Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 2.28e-3 |
Stromal cell | Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-4 | 2.85e-2 |
Stromal cell | Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-5 | 1.92e-2 |
Endothelial cell | Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 3.21e-2 |
Endothelial cell | Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-3 | 4.52e-2 |
Endothelial cell (APC) | Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 2.64e-2 |
Endothelial cell (APC) | Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-5 | 2.56e-2 |
Stromal cell | Osteoarthritis | Osteoarthritis | ETC | Tachmazidou | 2019 | 77052 | 378169 | 5.00e-2 | 1.98e-2 |
Endothelial cell (APC) | Osteoarthritis | Osteoarthritis of the hip or knee | ETC | Tachmazidou | 2019 | 39427 | 378169 | 5.00e-2 | 1.48e-2 |
Endothelial cell (APC) | Osteoarthritis | Osteoarthritis of the hip or knee | ETC | Tachmazidou | 2019 | 39427 | 378169 | 1.00e-2 | 1.80e-2 |
Stromal cell | Osteoarthritis | Osteoarthritis of the hip or knee | ETC | Tachmazidou | 2019 | 39427 | 378169 | 5.00e-2 | 1.48e-2 |
Fibroblast | Osteoarthritis | Osteoarthritis of the hip or knee | ETC | Tachmazidou | 2019 | 39427 | 378169 | 1.00e-2 | 1.24e-2 |
Endothelial cell | Osteoarthritis | Osteoarthritis of the hip or knee | ETC | Tachmazidou | 2019 | 39427 | 378169 | 1.00e-3 | 4.18e-2 |
Fibroblast | Osteoarthritis | Osteoarthritis hip | ETC | Tachmazidou | 2019 | 15704 | 378169 | 5.00e-2 | 1.37e-2 |
Endothelial cell (APC) | Osteoarthritis | Knee osteoarthritis | ETC | Tachmazidou | 2019 | 24955 | 376169 | 5.00e-2 | 1.47e-3 |
Endothelial cell (APC) | Osteoarthritis | Knee osteoarthritis | ETC | Tachmazidou | 2019 | 24955 | 376169 | 1.00e-2 | 4.25e-2 |
Stromal cell | Brain volume | White matter hyperintensity volume | ETC | Traylor | 2019 | NA | 8429 | 5.00e-2 | 1.74e-2 |
Macrophage | Brain volume | White matter hyperintensity volume | ETC | Traylor | 2019 | NA | 8429 | 5.00e-2 | 3.81e-2 |
Fibroblast | Brain volume | White matter hyperintensity volume | ETC | Traylor | 2019 | NA | 8429 | 1.00e-3 | 2.87e-2 |
Fibroblast | Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-3 | 2.47e-2 |
Endothelial cell (APC) | Life satisfaction | Life satisfaction | ETC | Baselmans | 2019 | NA | 80852 | 1.00e-2 | 2.95e-2 |
Loop of Henle | Erectile dysfunction | Erectile dysfunction | ETC | Bovijn | 2018 | 6175 | 217630 | 1.00e-2 | 4.36e-2 |
Macrophage | Erectile dysfunction | Erectile dysfunction | ETC | Bovijn | 2018 | 6175 | 217630 | 1.00e-3 | 1.58e-2 |
Endothelial cell (APC) | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 5.00e-2 | 4.96e-2 |
Endothelial cell (APC) | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-2 | 1.79e-3 |
Endothelial cell | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-2 | 3.53e-2 |
Macrophage | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-2 | 1.82e-2 |
Macrophage | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-3 | 1.14e-3 |
Endothelial cell | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 5.00e-2 | 1.86e-2 |
Endothelial cell | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-3 | 4.80e-2 |
Endothelial cell | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-4 | 4.13e-2 |
Endothelial cell (APC) | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-3 | 1.25e-2 |
Endothelial cell (APC) | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-4 | 4.13e-2 |
Endothelial cell (APC) | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-5 | 4.60e-2 |
Macrophage | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-4 | 4.13e-2 |
Macrophage | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-5 | 5.32e-3 |
Macrophage | Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 4.63e-2 |
Endothelial cell | Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-3 | 3.32e-2 |
Endothelial cell (APC) | Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-3 | 1.22e-2 |
Endothelial cell | Hippocampal volume | Hippocampal tail volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 2.68e-2 |
Endothelial cell | Fimbria volume | Fimbria volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.72e-3 |
Endothelial cell | Fimbria volume | Fimbria volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 2.37e-2 |
Fibroblast | Brain volume | Dentate gyrus molecular layer volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.96e-2 |
Fibroblast | Brain volume | Dentate gyrus molecular layer volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 4.84e-2 |
Stromal cell | Brain volume | Dentate gyrus molecular layer volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.96e-2 |
Stromal cell | Brain volume | Dentate gyrus molecular layer volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 4.84e-2 |
Smooth muscle cell | Brain volume | Dentate gyrus molecular layer volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 2.15e-2 |
Endothelial cell (APC) | Brain volume | Dentate gyrus granule cell layer volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 2.02e-2 |
Macrophage | Brain volume | Dentate gyrus granule cell layer volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 4.54e-3 |
Endothelial cell (APC) | Hippocampal volume | Hippocampal subfield CA4 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 4.36e-2 |
Stromal cell | Hippocampal volume | Hippocampal subfield CA4 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 4.36e-2 |
Macrophage | Hippocampal volume | Hippocampal subfield CA4 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 4.36e-2 |
Stromal cell | Hippocampal volume | Hippocampal subfield CA1 volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 4.85e-2 |
Macrophage | Presubiculum volume | Presubiculum volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 6.11e-3 |
Endothelial cell | Presubiculum volume | Presubiculum volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 4.84e-2 |
Macrophage | Hippocampal volume | Hippocampal fissure volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 4.55e-2 |
Loop of Henle | Hippocampal volume | Hippocampal fissure volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 2.70e-3 |
Loop of Henle | Hippocampal volume | Hippocampal subfield CA3 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.52e-2 |
Endothelial cell (APC) | Hippocampal volume | Hippocampal subfield CA3 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 1.34e-2 |
Smooth muscle cell | Parasubiculum volume | Presubiculum volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 4.13e-2 |
Endothelial cell (APC) | IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 5.00e-2 | 2.80e-2 |
Endothelial cell (APC) | IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-2 | 2.56e-2 |
Loop of Henle | IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-2 | 1.44e-2 |
Loop of Henle | IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-3 | 3.61e-3 |
Smooth muscle cell | IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-3 | 3.10e-2 |
Endothelial cell | ACR | Urinary albumin to creatinine ratio | ETC | Zanetti | 2019 | NA | 218759 | 1.00e-3 | 3.49e-2 |
Endothelial cell (APC) | ACR | Urinary albumin to creatinine ratio | ETC | Zanetti | 2019 | NA | 218759 | 1.00e-3 | 3.49e-2 |
Endothelial cell | Na/C | Urinary sodium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218450 | 5.00e-2 | 1.10e-2 |
Endothelial cell | Na/C | Urinary sodium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218450 | 1.00e-2 | 1.10e-2 |
Fibroblast | Na/C | Urinary sodium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218450 | 1.00e-4 | 3.29e-2 |
Fibroblast | AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 5.00e-2 | 3.69e-2 |
Endothelial cell | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 7.65e-3 |
Endothelial cell | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-2 | 3.58e-2 |
Endothelial cell | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-3 | 1.49e-2 |
Endothelial cell (APC) | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 2.44e-3 |
Endothelial cell (APC) | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-2 | 9.52e-3 |
Endothelial cell (APC) | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-3 | 6.82e-4 |
Endothelial cell (APC) | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-4 | 1.60e-5 |
Endothelial cell (APC) | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-5 | 2.94e-4 |
Fibroblast | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 1.09e-2 |
Stromal cell | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 3.87e-2 |
Endothelial cell | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 5.00e-2 | 1.04e-2 |
Endothelial cell | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-2 | 3.66e-2 |
Endothelial cell (APC) | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 5.00e-2 | 1.04e-2 |
Endothelial cell (APC) | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-2 | 3.66e-2 |
Endothelial cell (APC) | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-3 | 3.63e-2 |
Endothelial cell (APC) | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-4 | 3.52e-3 |
Endothelial cell (APC) | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-5 | 2.47e-4 |
Endothelial cell | Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 5.00e-2 | 3.06e-3 |
Endothelial cell (APC) | Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 5.00e-2 | 1.39e-2 |
Endothelial cell (APC) | Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 1.00e-4 | 4.51e-3 |
Endothelial cell (APC) | Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 1.00e-5 | 7.17e-3 |
Smooth muscle cell | Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 1.00e-4 | 1.58e-2 |
Smooth muscle cell | Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 1.00e-5 | 7.17e-3 |
Smooth muscle cell | Medication use | Medication use (vasodilators used in cardiac diseases) | ETC | Wu Y | 2019 | 5,546 | 237,113 | 1.00e-2 | 5.87e-3 |
Smooth muscle cell | Medication use | Medication use (vasodilators used in cardiac diseases) | ETC | Wu Y | 2019 | 5,546 | 237,113 | 1.00e-4 | 1.35e-2 |
Endothelial cell (APC) | Medication use | Medication use (antihypertensives) | ETC | Wu Y | 2019 | 6,431 | 145,949 | 5.00e-2 | 1.03e-3 |
Endothelial cell (APC) | Medication use | Medication use (beta blocking agents) | ETC | Wu Y | 2019 | 31,700 | 192,324 | 5.00e-2 | 3.01e-2 |
Endothelial cell (APC) | Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 5.00e-2 | 4.62e-2 |
Endothelial cell | Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-3 | 1.99e-2 |
Endothelial cell | Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-4 | 2.38e-3 |
Endothelial cell | Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-5 | 2.19e-3 |
Endothelial cell | Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 5.00e-2 | 2.25e-2 |
Endothelial cell | Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 1.00e-2 | 5.94e-3 |
Endothelial cell | Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 1.00e-3 | 1.11e-2 |
Endothelial cell (APC) | Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 5.00e-2 | 5.10e-4 |
Endothelial cell (APC) | Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 1.00e-2 | 1.87e-3 |
Endothelial cell (APC) | Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 1.00e-3 | 2.68e-3 |
Endothelial cell (APC) | Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 1.00e-4 | 1.54e-2 |
Endothelial cell (APC) | Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 5.00e-2 | 3.94e-2 |
Endothelial cell (APC) | Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-2 | 6.07e-4 |
Endothelial cell (APC) | Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-3 | 5.82e-3 |
Endothelial cell (APC) | Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-4 | 1.84e-3 |
Endothelial cell (APC) | Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-5 | 1.36e-2 |
Endothelial cell | Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-3 | 3.91e-3 |
Endothelial cell | Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-4 | 3.08e-3 |
Endothelial cell | Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-5 | 2.58e-3 |
Endothelial cell (APC) | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 5.00e-2 | 1.72e-2 |
Endothelial cell (APC) | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-2 | 2.76e-2 |
Endothelial cell (APC) | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-4 | 1.14e-2 |
Endothelial cell (APC) | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-5 | 5.79e-3 |
Endothelial cell | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-5 | 3.49e-2 |
Macrophage | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-5 | 3.49e-2 |
Endothelial cell | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 5.00e-2 | 5.76e-3 |
Endothelial cell | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-2 | 2.57e-3 |
Endothelial cell | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-3 | 1.34e-3 |
Endothelial cell | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-4 | 6.46e-5 |
Endothelial cell | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-5 | 3.63e-5 |
Endothelial cell (APC) | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 5.00e-2 | 4.20e-3 |
Endothelial cell (APC) | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-2 | 7.85e-3 |
Endothelial cell (APC) | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-3 | 5.55e-3 |
Endothelial cell (APC) | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-4 | 1.83e-2 |
Endothelial cell (APC) | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-5 | 1.41e-3 |
Macrophage | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-3 | 2.80e-2 |
Endothelial cell | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 5.00e-2 | 8.73e-3 |
Endothelial cell | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-2 | 1.26e-3 |
Endothelial cell | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-3 | 1.66e-5 |
Endothelial cell | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-4 | 4.88e-5 |
Endothelial cell | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-5 | 6.25e-6 |
Endothelial cell (APC) | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 5.00e-2 | 1.24e-3 |
Endothelial cell (APC) | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-2 | 5.73e-4 |
Endothelial cell (APC) | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-3 | 4.29e-6 |
Endothelial cell (APC) | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-4 | 1.12e-5 |
Endothelial cell (APC) | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-5 | 6.25e-6 |
Macrophage | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 5.00e-2 | 1.35e-2 |
Macrophage | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-2 | 5.73e-4 |
Macrophage | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-3 | 6.44e-4 |
Macrophage | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-4 | 7.54e-3 |
Macrophage | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-5 | 7.14e-3 |
Fibroblast | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-5 | 2.13e-2 |
Endothelial cell | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 5.00e-2 | 1.34e-2 |
Endothelial cell | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-2 | 2.17e-3 |
Endothelial cell | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-3 | 4.80e-2 |
Endothelial cell | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-4 | 4.33e-2 |
Fibroblast | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-3 | 2.87e-3 |
Fibroblast | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-4 | 1.67e-2 |
Macrophage | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-3 | 6.31e-3 |
Stromal cell | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-4 | 4.33e-2 |
Endothelial cell (APC) | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 5.00e-2 | 7.08e-3 |
Endothelial cell (APC) | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-2 | 2.74e-3 |
Stromal cell | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 5.00e-2 | 2.21e-2 |
Loop of Henle | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 5.00e-2 | 4.31e-2 |
Loop of Henle | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-2 | 9.09e-3 |
Loop of Henle | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-3 | 4.81e-3 |
Loop of Henle | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-4 | 2.14e-2 |
Loop of Henle | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-5 | 7.11e-3 |
Endothelial cell | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-2 | 1.57e-2 |
Endothelial cell | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-3 | 1.23e-2 |
Fibroblast | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-2 | 9.09e-3 |
Fibroblast | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-3 | 2.63e-2 |
Macrophage | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-4 | 2.76e-2 |
Macrophage | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-5 | 5.78e-4 |
Endothelial cell | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-5 | 1.22e-2 |
Endothelial cell (APC) | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 5.00e-2 | 4.01e-2 |
Endothelial cell (APC) | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-2 | 1.45e-3 |
Endothelial cell (APC) | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-3 | 1.40e-3 |
Endothelial cell (APC) | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-4 | 9.33e-3 |
Fibroblast | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 5.00e-2 | 6.45e-3 |
Fibroblast | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-2 | 1.64e-2 |
Fibroblast | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-3 | 9.61e-3 |
Loop of Henle | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 5.00e-2 | 4.01e-2 |
Loop of Henle | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-2 | 2.80e-3 |
Endothelial cell | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-3 | 4.83e-2 |
Endothelial cell | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-4 | 9.33e-3 |
Macrophage | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-3 | 2.24e-2 |
Endothelial cell (APC) | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-3 | 3.52e-3 |
Endothelial cell (APC) | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-4 | 1.84e-4 |
Endothelial cell (APC) | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-5 | 8.36e-6 |
Endothelial cell | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-4 | 8.54e-3 |
Endothelial cell | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-5 | 1.68e-3 |
Fibroblast | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-5 | 3.56e-2 |
Loop of Henle | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-5 | 3.56e-2 |
Smooth muscle cell | Medication use | Medication use (antimigraine preparations) | ETC | Wu Y | 2019 | 5,521 | 114,323 | 5.00e-2 | 4.62e-2 |
Macrophage | Medication use | Medication use (antimigraine preparations) | ETC | Wu Y | 2019 | 5,521 | 114,323 | 1.00e-4 | 2.37e-2 |
Endothelial cell (APC) | Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 5.00e-2 | 2.60e-4 |
Endothelial cell (APC) | Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 1.00e-2 | 3.47e-2 |
Fibroblast | Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 5.00e-2 | 1.04e-2 |
Fibroblast | Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 1.00e-2 | 2.09e-2 |
Endothelial cell | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 5.00e-2 | 4.32e-3 |
Endothelial cell | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-2 | 1.23e-3 |
Endothelial cell | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-3 | 8.11e-3 |
Endothelial cell | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-4 | 3.31e-2 |
Endothelial cell | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-5 | 1.17e-2 |
Endothelial cell (APC) | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 5.00e-2 | 1.43e-3 |
Endothelial cell (APC) | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-2 | 4.44e-4 |
Endothelial cell (APC) | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-3 | 8.11e-3 |
Endothelial cell (APC) | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-4 | 4.83e-4 |
Endothelial cell (APC) | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-5 | 4.15e-5 |
Macrophage | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-5 | 1.17e-2 |
Endothelial cell | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 5.00e-2 | 4.48e-3 |
Endothelial cell | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-2 | 4.05e-2 |
Endothelial cell | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-3 | 4.44e-2 |
Endothelial cell | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-4 | 1.19e-3 |
Endothelial cell | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-5 | 8.39e-5 |
Endothelial cell (APC) | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 5.00e-2 | 5.36e-4 |
Endothelial cell (APC) | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-2 | 6.69e-3 |
Endothelial cell (APC) | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-3 | 6.47e-3 |
Endothelial cell (APC) | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-4 | 1.19e-3 |
Endothelial cell (APC) | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-5 | 8.39e-5 |
Loop of Henle | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-2 | 2.68e-2 |
Fibroblast | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-3 | 4.44e-2 |
Macrophage | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-3 | 4.44e-2 |
Macrophage | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-4 | 1.19e-3 |
Macrophage | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-5 | 1.12e-3 |
Endothelial cell | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 5.00e-2 | 3.71e-3 |
Endothelial cell | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-2 | 1.52e-3 |
Endothelial cell | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-3 | 3.59e-4 |
Endothelial cell | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-4 | 1.77e-3 |
Endothelial cell (APC) | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 5.00e-2 | 2.75e-2 |
Endothelial cell (APC) | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-2 | 3.44e-2 |
Endothelial cell (APC) | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-4 | 3.22e-2 |
Macrophage | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-2 | 1.11e-2 |
Macrophage | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-3 | 2.95e-2 |
Macrophage | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-4 | 8.24e-3 |
Endothelial cell (APC) | Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 5.00e-2 | 2.30e-2 |
Endothelial cell (APC) | Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-2 | 1.69e-2 |
Endothelial cell (APC) | Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-3 | 2.87e-2 |
Endothelial cell (APC) | Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-5 | 3.75e-2 |
Loop of Henle | Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 5.00e-2 | 2.30e-2 |
Loop of Henle | Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-2 | 1.69e-2 |
Loop of Henle | Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-3 | 4.04e-3 |
Endothelial cell (APC) | Glomerular filtration rate | Estimated glomerular filtration rate | ETC | Wuttke M | 2019 | NA | 567,460 | 1.00e-2 | 3.46e-2 |
Endothelial cell (APC) | Glomerular filtration rate | Estimated glomerular filtration rate | ETC | Wuttke M | 2019 | NA | 567,460 | 1.00e-3 | 2.61e-2 |
Endothelial cell (APC) | Glomerular filtration rate | Estimated glomerular filtration rate | ETC | Wuttke M | 2019 | NA | 567,460 | 1.00e-4 | 3.50e-2 |
Endothelial cell (APC) | Glomerular filtration rate | Estimated glomerular filtration rate | ETC | Wuttke M | 2019 | NA | 567,460 | 1.00e-5 | 2.90e-2 |
Loop of Henle | CKD | Chronic kidney disease | ETC | Wuttke M | 2019 | 64,164 | 561,055 | 5.00e-2 | 1.54e-2 |
Endothelial cell (APC) | CKD | Chronic kidney disease | ETC | Wuttke M | 2019 | 64,164 | 561,055 | 1.00e-2 | 1.97e-2 |
Endothelial cell (APC) | CKD | Chronic kidney disease | ETC | Wuttke M | 2019 | 64,164 | 561,055 | 1.00e-3 | 2.31e-2 |
Endothelial cell | Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 5.00e-2 | 4.16e-3 |
Endothelial cell | Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-2 | 1.26e-2 |
Endothelial cell | Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-3 | 4.96e-2 |
Endothelial cell | Periodontal disease | Periodontal disease related phenotype (PCT2) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 4.75e-4 |
Endothelial cell | Periodontal disease | Periodontal disease related phenotype (PCT2) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 1.19e-2 |
Macrophage | Periodontal disease | Periodontal disease related phenotype (PCT2) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 2.94e-2 |
Smooth muscle cell | Periodontal disease | Periodontal disease related phenotype (PCT3) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 3.63e-2 |
Smooth muscle cell | Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 5.51e-3 |
Fibroblast | Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 2.36e-4 |
Stromal cell | Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 3.11e-3 |
Stromal cell | Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 1.15e-2 |
Endothelial cell (APC) | Periodontal disease | Periodontal disease related phenotype (PCT5) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 4.59e-2 |
Stromal cell | Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 3.34e-2 |
Stromal cell | Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 4.83e-2 |
Loop of Henle | Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 3.34e-2 |
Loop of Henle | Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 4.83e-2 |
Endothelial cell | Nonalcoholic Liver disease | Non-alcoholic fatty liver disease activity score | ETC | Namjou B | 2019 | NA | 235 | 1.00e-2 | 1.81e-2 |
Endothelial cell (APC) | Nonalcoholic Liver disease | Non-alcoholic fatty liver disease activity score | ETC | Namjou B | 2019 | NA | 235 | 1.00e-2 | 5.88e-3 |
Loop of Henle | Nonalcoholic Liver disease | Non-alcoholic fatty liver disease activity score | ETC | Namjou B | 2019 | NA | 235 | 1.00e-2 | 1.81e-2 |
Macrophage | Nonalcoholic Liver disease | Non-alcoholic fatty liver disease activity score | ETC | Namjou B | 2019 | NA | 235 | 1.00e-2 | 1.81e-2 |
Smooth muscle cell | Autistic traits score | Autistic traits score (Social and Communication Disorders Checklist) | ETC | Massrali A | 2019 | NA | 5,628 | 5.00e-2 | 3.01e-2 |
Endothelial cell (APC) | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 2,010 | 5,145 | 5.00e-2 | 2.86e-2 |
Endothelial cell | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 2,010 | 5,145 | 1.00e-2 | 4.17e-2 |
Fibroblast | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 7,834 | 15,258 | 5.00e-2 | 2.57e-2 |
Fibroblast | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 7,834 | 15,258 | 1.00e-2 | 3.97e-2 |
Stromal cell | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 7,834 | 15,258 | 5.00e-2 | 3.98e-2 |
Stromal cell | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 9,844 | 20,403 | 1.00e-2 | 8.75e-3 |
Fibroblast | Longevity | Longevity (age >90th survival percentile) | ETC | Deelen J | 2019 | 11,262 | 25,483 | 5.00e-2 | 8.49e-3 |
Stromal cell | Longevity | Longevity (age >90th survival percentile) | ETC | Deelen J | 2019 | 11,262 | 25,483 | 5.00e-2 | 1.33e-2 |
Endothelial cell (APC) | Longevity | Longevity (age >99th survival percentile) | ETC | Deelen J | 2019 | 3,484 | 25,483 | 5.00e-2 | 6.11e-3 |
Fibroblast | Longevity | Longevity (age >99th survival percentile) | ETC | Deelen J | 2019 | 3,484 | 25,483 | 5.00e-2 | 3.39e-2 |
Fibroblast | Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-4 | 3.21e-2 |
Fibroblast | Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-5 | 2.48e-2 |
Endothelial cell | Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-5 | 2.48e-2 |
Endothelial cell | Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 5.00e-2 | 1.77e-2 |
Endothelial cell (APC) | Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-3 | 4.30e-3 |
Endothelial cell (APC) | Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-5 | 2.44e-2 |
Stromal cell | same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 5.00e-2 | 1.01e-2 |
Endothelial cell (APC) | same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-2 | 4.65e-3 |
Loop of Henle | same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-2 | 2.10e-2 |
Loop of Henle | same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-3 | 4.36e-2 |
Macrophage | same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-2 | 4.10e-2 |
Macrophage | same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-3 | 4.36e-2 |
Stromal cell | same-sex sexual behaviour | same-sex sexual behaviour Female | ETC | Ganna A | 2019 | NA | 220,170 | 1.00e-2 | 3.82e-2 |
Stromal cell | same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 5.00e-2 | 1.32e-2 |
Stromal cell | same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 1.00e-2 | 4.62e-2 |
Endothelial cell (APC) | same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 1.00e-2 | 4.62e-2 |
Loop of Henle | same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 1.00e-2 | 2.52e-2 |
Endothelial cell | Knee pain | Knee pain | ETC | Meng W | 2019 | 22,204 | 149,312 | 1.00e-3 | 3.79e-2 |
Endothelial cell (APC) | Occipital lobe volume | Occipital lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 2.03e-3 |
Macrophage | Birth | Post-term birth | ETC | Liu X | 2019 | 7,888 | 60,148 | 1.00e-2 | 3.19e-2 |
Macrophage | Birth | Post-term birth | ETC | Liu X | 2019 | 7,888 | 60,148 | 1.00e-3 | 1.83e-3 |
Smooth muscle cell | Birth | Early spontaneous preterm birth | ETC | Liu X | 2019 | 1,139 | 60,148 | 5.00e-2 | 1.40e-2 |
Endothelial cell (APC) | Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 1.00e-2 | 4.23e-2 |
Endothelial cell (APC) | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 5.00e-2 | 2.10e-2 |
Endothelial cell (APC) | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-2 | 2.25e-4 |
Endothelial cell (APC) | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-3 | 8.99e-3 |
Endothelial cell (APC) | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-4 | 5.49e-3 |
Endothelial cell (APC) | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-5 | 7.74e-3 |
Stromal cell | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-2 | 1.53e-2 |
Stromal cell | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-4 | 3.04e-2 |
Fibroblast | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-3 | 2.25e-2 |
Fibroblast | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-4 | 3.04e-2 |
Endothelial cell | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 5.00e-2 | 2.87e-2 |
Endothelial cell | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-2 | 4.01e-3 |
Endothelial cell | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-4 | 2.19e-2 |
Endothelial cell (APC) | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-3 | 1.43e-3 |
Endothelial cell (APC) | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-4 | 1.50e-4 |
Endothelial cell (APC) | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-5 | 5.73e-4 |
Macrophage | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-4 | 3.53e-2 |
Macrophage | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-5 | 1.92e-2 |
Endothelial cell | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 5.00e-2 | 1.07e-2 |
Endothelial cell | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-2 | 7.60e-4 |
Endothelial cell | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-4 | 1.56e-2 |
Endothelial cell (APC) | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 5.00e-2 | 8.61e-4 |
Endothelial cell (APC) | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-2 | 1.26e-3 |
Endothelial cell (APC) | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-3 | 5.33e-3 |
Endothelial cell (APC) | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-4 | 1.92e-3 |
Macrophage | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-2 | 1.74e-2 |
Macrophage | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-3 | 2.94e-3 |
Macrophage | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-4 | 1.92e-3 |
Macrophage | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-5 | 4.13e-4 |
Endothelial cell (APC) | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 5.00e-2 | 1.44e-2 |
Stromal cell | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-2 | 3.72e-2 |
Macrophage | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-5 | 4.42e-2 |
Endothelial cell (APC) | Urate | Urate levels | ETC | Tin A | 2019 | NA | 288,649 | 1.00e-2 | 7.14e-3 |
Endothelial cell (APC) | Urate | Urate levels | ETC | Tin A | 2019 | NA | 288,649 | 1.00e-5 | 4.75e-2 |
Endothelial cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-2 | 9.03e-3 |
Endothelial cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-3 | 2.92e-3 |
Endothelial cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-4 | 7.39e-3 |
Endothelial cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-5 | 3.33e-3 |
Endothelial cell (APC) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-2 | 1.42e-5 |
Endothelial cell (APC) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-3 | 4.50e-6 |
Endothelial cell (APC) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-4 | 2.42e-6 |
Endothelial cell (APC) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-5 | 3.57e-5 |
Stromal cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-2 | 5.11e-3 |
Stromal cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-3 | 2.92e-3 |
Stromal cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-4 | 1.59e-3 |
Stromal cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-5 | 8.51e-4 |
Fibroblast | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-4 | 2.75e-2 |
Fibroblast | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-5 | 2.31e-2 |
Endothelial cell (APC) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 5.00e-2 | 6.93e-3 |
Endothelial cell (APC) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-2 | 2.35e-3 |
Endothelial cell (APC) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-3 | 1.98e-2 |
Endothelial cell (APC) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-4 | 4.58e-3 |
Stromal cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 5.00e-2 | 5.31e-5 |
Stromal cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-2 | 3.57e-5 |
Stromal cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-3 | 4.32e-3 |
Stromal cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-5 | 3.90e-2 |
Endothelial cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-3 | 7.20e-4 |
Endothelial cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-4 | 2.77e-3 |
Endothelial cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-5 | 3.90e-2 |
Stromal cell | Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-3 | 1.41e-3 |
Stromal cell | Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-4 | 2.06e-2 |
Endothelial cell (APC) | Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-4 | 4.53e-2 |
Endothelial cell | Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-2 | 3.24e-2 |
Endothelial cell | Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-4 | 4.31e-2 |
Endothelial cell | Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-5 | 3.74e-2 |
Endothelial cell (APC) | Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-2 | 2.74e-3 |
Endothelial cell (APC) | Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-3 | 1.47e-3 |
Endothelial cell (APC) | Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-4 | 2.34e-2 |
Endothelial cell (APC) | Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-3 | 1.84e-2 |
Endothelial cell (APC) | Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-4 | 3.04e-2 |
Endothelial cell (APC) | Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-5 | 1.47e-2 |
Endothelial cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-3 | 3.44e-4 |
Endothelial cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-4 | 1.71e-4 |
Endothelial cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-5 | 1.96e-3 |
Endothelial cell (APC) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-3 | 1.84e-5 |
Endothelial cell (APC) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-4 | 2.11e-6 |
Endothelial cell (APC) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-5 | 5.61e-4 |
Stromal cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-3 | 4.47e-5 |
Stromal cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-4 | 2.72e-5 |
Stromal cell | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-5 | 5.34e-5 |
Endothelial cell | Joint damage | Joint damage in rheumatoid arthritis | ETC | Traylor M | 2019 | NA | 2,527 | 1.00e-2 | 3.30e-2 |
Stromal cell | Joint damage | Joint damage in rheumatoid arthritis | ETC | Traylor M | 2019 | NA | 2,527 | 1.00e-2 | 1.37e-2 |
Macrophage | Joint damage | Joint damage in rheumatoid arthritis | ETC | Traylor M | 2019 | NA | 2,527 | 1.00e-2 | 5.21e-3 |
Endothelial cell (APC) | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-2 | 9.81e-3 |
Endothelial cell (APC) | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-3 | 9.55e-5 |
Endothelial cell (APC) | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-4 | 9.72e-4 |
Endothelial cell (APC) | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-5 | 2.55e-3 |
Fibroblast | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-2 | 3.44e-2 |
Stromal cell | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-2 | 1.88e-2 |
Loop of Henle | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-2 | 9.81e-3 |
Macrophage | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-2 | 3.44e-2 |
Macrophage | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-3 | 1.13e-2 |
Endothelial cell | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-3 | 3.93e-3 |
Endothelial cell (APC) | Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-3 | 4.98e-2 |
Endothelial cell (APC) | Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-4 | 4.30e-3 |
Endothelial cell (APC) | Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-5 | 2.14e-2 |
Endothelial cell (APC) | BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-3 | 9.74e-3 |
Endothelial cell (APC) | BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-4 | 1.21e-3 |
Endothelial cell (APC) | BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-5 | 2.40e-4 |
Endothelial cell | BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-5 | 1.67e-2 |
Loop of Henle | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-2 | 1.80e-2 |
Endothelial cell (APC) | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-3 | 6.01e-4 |
Endothelial cell (APC) | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-4 | 7.38e-3 |
Endothelial cell (APC) | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-5 | 5.30e-3 |
Endothelial cell (APC) | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-2 | 1.78e-2 |
Endothelial cell (APC) | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-3 | 7.62e-4 |
Endothelial cell (APC) | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-4 | 4.86e-4 |
Endothelial cell (APC) | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-5 | 5.16e-4 |
Stromal cell | Height | Height variance | ETC | Wang H | 2019 | NA | 347,086 | 5.00e-2 | 4.73e-2 |
Endothelial cell (APC) | Lung function | Lung function (FEV1/FVC) variance | ETC | Wang H | 2019 | NA | 316,614 | 5.00e-2 | 2.85e-4 |
Endothelial cell (APC) | Lung function | Lung function (FEV1/FVC) variance | ETC | Wang H | 2019 | NA | 316,614 | 1.00e-2 | 5.60e-3 |
Macrophage | Lung function | Lung function (FEV1/FVC) variance | ETC | Wang H | 2019 | NA | 316,614 | 5.00e-2 | 1.76e-2 |
Macrophage | Lung function | Lung function (FEV1/FVC) variance | ETC | Wang H | 2019 | NA | 316,614 | 1.00e-2 | 5.60e-3 |
Endothelial cell (APC) | Heel bone mineral Density | Heel bone mineral density variance | ETC | Wang H | 2019 | NA | 197,261 | 5.00e-2 | 1.51e-2 |
Endothelial cell (APC) | Heel bone mineral Density | Heel bone mineral density variance | ETC | Wang H | 2019 | NA | 197,261 | 1.00e-2 | 3.05e-2 |
Loop of Henle | Waist to hip ratio | BMI-adjusted waist-hip ratio variance | ETC | Wang H | 2019 | NA | 346,535 | 5.00e-2 | 4.58e-2 |
Endothelial cell | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 5.00e-2 | 8.49e-3 |
Endothelial cell | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-2 | 2.14e-4 |
Endothelial cell | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-3 | 9.43e-4 |
Endothelial cell | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-4 | 4.83e-3 |
Endothelial cell | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-5 | 1.92e-3 |
Endothelial cell (APC) | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 5.00e-2 | 1.12e-3 |
Endothelial cell (APC) | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-2 | 5.11e-4 |
Endothelial cell (APC) | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-3 | 7.59e-3 |
Endothelial cell (APC) | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-4 | 4.83e-3 |
Endothelial cell (APC) | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-5 | 1.92e-3 |
Macrophage | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 5.00e-2 | 5.30e-3 |
Macrophage | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-2 | 2.56e-3 |
Macrophage | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-3 | 2.96e-4 |
Macrophage | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-4 | 1.47e-3 |
Macrophage | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-5 | 4.64e-4 |
Smooth muscle cell | Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 5.00e-2 | 2.70e-3 |
Stromal cell | Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-3 | 3.86e-2 |
Macrophage | Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-3 | 3.86e-2 |
Endothelial cell (APC) | Uterine fibroids and heavy menstrual bleeding | Uterine fibroids and heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 3,409 | 199,171 | 5.00e-2 | 2.81e-2 |
Stromal cell | Uterine fibroids and heavy menstrual bleeding | Uterine fibroids and heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 3,409 | 199,171 | 5.00e-2 | 1.88e-2 |
Stromal cell | Heavy menstrual bleeding | Heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 9,813 | 210,946 | 5.00e-2 | 1.50e-2 |
Stromal cell | Heavy menstrual bleeding | Heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 9,813 | 210,946 | 1.00e-2 | 4.87e-3 |
Endothelial cell | Uterine fibroids | Uterine fibroids | ETC | Gallagher CS | 2019 | 20,406 | 223,918 | 1.00e-4 | 3.44e-2 |
Stromal cell | Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-3 | 5.32e-3 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 5.00e-2 | 8.07e-3 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-2 | 5.80e-3 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-3 | 5.07e-3 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-4 | 1.65e-4 |
Endothelial cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-3 | 5.07e-3 |
Endothelial cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-4 | 1.65e-4 |
Endothelial cell (APC) | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-3 | 1.74e-2 |
Endothelial cell (APC) | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-4 | 1.19e-3 |
Fibroblast | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 5.00e-2 | 4.10e-2 |
Fibroblast | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-3 | 2.14e-2 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-3 | 2.14e-2 |
Endothelial cell (APC) | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 5.00e-2 | 1.70e-2 |
Endothelial cell (APC) | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-2 | 1.18e-3 |
Endothelial cell (APC) | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-3 | 7.14e-3 |
Endothelial cell (APC) | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-4 | 1.88e-2 |
Endothelial cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-2 | 1.13e-2 |
Endothelial cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-3 | 2.14e-3 |
Endothelial cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-4 | 4.74e-5 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-2 | 1.13e-2 |
Macrophage | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-4 | 3.21e-3 |
Macrophage | BMI by age | BMI at 6 weeks old | ETC | Helgeland O | 2019 | NA | 6,450 | 5.00e-2 | 4.72e-2 |
Macrophage | BMI by age | BMI at 6 weeks old | ETC | Helgeland O | 2019 | NA | 6,450 | 1.00e-2 | 7.00e-3 |
Loop of Henle | BMI by age | BMI at 3 months old | ETC | Helgeland O | 2019 | NA | 7,970 | 5.00e-2 | 1.58e-2 |
Stromal cell | BMI by age | BMI at 3 months old | ETC | Helgeland O | 2019 | NA | 7,970 | 1.00e-2 | 3.19e-2 |
Endothelial cell (APC) | BMI by age | BMI at 6 months old | ETC | Helgeland O | 2019 | NA | 8,017 | 5.00e-2 | 2.71e-2 |
Endothelial cell (APC) | BMI by age | BMI at 8 months old | ETC | Helgeland O | 2019 | NA | 7,197 | 5.00e-2 | 7.78e-3 |
Endothelial cell | BMI by age | BMI at 1 year old | ETC | Helgeland O | 2019 | NA | 6,970 | 1.00e-2 | 3.29e-2 |
Endothelial cell | BMI by age | BMI at 1 year old | ETC | Helgeland O | 2019 | NA | 6,970 | 1.00e-3 | 4.08e-2 |
Endothelial cell | BMI by age | BMI at 1.5 years old | ETC | Helgeland O | 2019 | NA | 6,800 | 5.00e-2 | 1.30e-2 |
Endothelial cell | BMI by age | BMI at 1.5 years old | ETC | Helgeland O | 2019 | NA | 6,800 | 1.00e-2 | 2.68e-3 |
Endothelial cell | BMI by age | BMI at 1.5 years old | ETC | Helgeland O | 2019 | NA | 6,800 | 1.00e-3 | 1.16e-2 |
Endothelial cell (APC) | BMI by age | BMI at 2 years old | ETC | Helgeland O | 2019 | NA | 4,631 | 1.00e-2 | 3.05e-2 |
Smooth muscle cell | BMI by age | BMI at 2 years old | ETC | Helgeland O | 2019 | NA | 4,631 | 1.00e-3 | 4.36e-2 |
Stromal cell | BMI by age | BMI at 2 years old | ETC | Helgeland O | 2019 | NA | 4,631 | 1.00e-3 | 4.36e-2 |
Loop of Henle | BMI by age | BMI at 3 years old | ETC | Helgeland O | 2019 | NA | 5,069 | 5.00e-2 | 2.82e-2 |
Smooth muscle cell | BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 5.00e-2 | 8.80e-4 |
Fibroblast | BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 5.00e-2 | 4.77e-4 |
Endothelial cell (APC) | BMI by age | BMI at 7 years old | ETC | Helgeland O | 2019 | NA | 4,629 | 1.00e-2 | 1.71e-2 |
Endothelial cell (APC) | BMI by age | BMI at 7 years old | ETC | Helgeland O | 2019 | NA | 4,629 | 1.00e-3 | 6.19e-3 |
Endothelial cell | PD | Parkinson's disease in GBA mutation carriers (age at onset) | ETC | Blauwendraat C | 2020 | NA | 1,353 | 5.00e-2 | 3.92e-3 |
Endothelial cell | PD | Parkinson's disease in GBA mutation carriers (age at onset) | ETC | Blauwendraat C | 2020 | NA | 1,353 | 1.00e-2 | 1.67e-2 |
Endothelial cell | Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 5.00e-2 | 1.90e-2 |
Endothelial cell | Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 1.00e-3 | 3.46e-3 |
Endothelial cell (APC) | Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 5.00e-2 | 1.35e-3 |
Endothelial cell (APC) | Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 1.00e-2 | 4.55e-3 |
Stromal cell | Left ventricular | Left ventricular ejection fraction | ETC | Aung N | 2019 | NA | 16,923 | 1.00e-2 | 1.53e-2 |
Stromal cell | Left ventricular | Left ventricular ejection fraction | ETC | Aung N | 2019 | NA | 16,923 | 1.00e-3 | 3.99e-2 |
Smooth muscle cell | Left ventricular | Left ventricular ejection fraction | ETC | Aung N | 2019 | NA | 16,923 | 1.00e-3 | 1.40e-2 |
Endothelial cell (APC) | Left ventricular | Left ventricular mass | ETC | Aung N | 2019 | NA | 16,920 | 5.00e-2 | 3.57e-2 |
Endothelial cell | Left ventricular | Left ventricular end-diastolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-3 | 7.06e-3 |
Endothelial cell (APC) | Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 5.00e-2 | 3.10e-2 |
Endothelial cell (APC) | Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-2 | 1.05e-2 |
Endothelial cell (APC) | Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-3 | 2.00e-2 |
Endothelial cell (APC) | Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 5.00e-2 | 5.38e-4 |
Endothelial cell (APC) | Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-2 | 4.37e-2 |
Endothelial cell (APC) | Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-3 | 3.75e-2 |
Fibroblast | Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-2 | 4.37e-2 |
Stromal cell | Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-3 | 3.75e-2 |
Stromal cell | Central corneal thickness | Central corneal thickness | ETC | Bonnemaijer PWM | 2019 | NA | 16,204 | 5.00e-2 | 2.07e-3 |
Stromal cell | Central corneal thickness | Central corneal thickness | ETC | Bonnemaijer PWM | 2019 | NA | 16,204 | 1.00e-2 | 1.92e-3 |
Stromal cell | Central corneal thickness | Central corneal thickness | ETC | Bonnemaijer PWM | 2019 | NA | 16,204 | 1.00e-4 | 3.99e-2 |
Stromal cell | Central corneal thickness | Central corneal thickness | ETC | Bonnemaijer PWM | 2019 | NA | 16,204 | 1.00e-5 | 2.87e-2 |
Fibroblast | Central corneal thickness | Central corneal thickness | ETC | Bonnemaijer PWM | 2019 | NA | 16,204 | 1.00e-2 | 2.87e-2 |
Smooth muscle cell | Temporale grey matter volume | Right planum temporale grey matter volume | ETC | Carrion-Castillo A | 2020 | NA | 18,039 | 5.00e-2 | 3.47e-2 |
Endothelial cell | Temporale grey matter volume | Left planum temporale grey matter volume | ETC | Carrion-Castillo A | 2020 | NA | 18,037 | 5.00e-2 | 4.46e-2 |
Smooth muscle cell | Temporale grey matter volume | Left planum temporale grey matter volume | ETC | Carrion-Castillo A | 2020 | NA | 18,037 | 5.00e-2 | 2.29e-2 |
Endothelial cell | Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-2 | 4.39e-2 |
Stromal cell | Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-2 | 1.45e-2 |
Stromal cell | Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-3 | 1.00e-2 |
Stromal cell | Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-4 | 4.62e-2 |
Stromal cell | Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-5 | 2.32e-2 |
Fibroblast | Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 5.00e-2 | 4.15e-2 |
Fibroblast | Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-3 | 4.82e-2 |
Fibroblast | Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-4 | 2.42e-2 |
Stromal cell | Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 5.00e-2 | 2.61e-2 |
Endothelial cell (APC) | Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-2 | 2.94e-2 |
Endothelial cell (APC) | Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-3 | 3.47e-2 |
Endothelial cell (APC) | Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 5.00e-2 | 1.57e-2 |
Endothelial cell (APC) | Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 1.00e-2 | 2.23e-3 |
Endothelial cell (APC) | Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 1.00e-3 | 3.72e-3 |
Endothelial cell (APC) | Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 1.00e-4 | 1.60e-2 |
Endothelial cell (APC) | Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 1.00e-5 | 1.11e-2 |
Macrophage | Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 1.00e-4 | 4.86e-2 |
Macrophage | Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 1.00e-5 | 2.32e-2 |
Endothelial cell (APC) | Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-2 | 1.02e-2 |
Endothelial cell (APC) | Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-3 | 2.29e-2 |
Endothelial cell (APC) | Household income (MTAG) | Household income (MTAG) | ETC | Hill WD | 2019 | NA | 505,541 | 1.00e-4 | 4.95e-3 |
Fibroblast | Heart failure | Heart failure | ETC | Shah S | 2020 | 47,309 | 930,014 | 5.00e-2 | 2.59e-2 |
Smooth muscle cell | Heart failure | Heart failure | ETC | Shah S | 2020 | 47,309 | 930,014 | 1.00e-2 | 4.61e-2 |
Loop of Henle | Heart failure | Heart failure | ETC | Shah S | 2020 | 47,309 | 930,014 | 1.00e-2 | 4.61e-2 |
Macrophage | CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 1.90e-2 |
Macrophage | CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 5.80e-3 |
Macrophage | CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.70e-3 |
Smooth muscle cell | CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 4.33e-2 |
Stromal cell | CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 4.33e-2 |
Stromal cell | CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.93e-2 |
Stromal cell | IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 4.05e-2 |
Stromal cell | IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 8.44e-3 |
Stromal cell | IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 2.07e-2 |
Stromal cell | IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.52e-3 |
Macrophage | IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 3.35e-2 |
Macrophage | IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.43e-2 |
Smooth muscle cell | C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.68e-2 |
Smooth muscle cell | C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 4.38e-2 |
Smooth muscle cell | C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.55e-2 |
Smooth muscle cell | C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.29e-2 |
Macrophage | C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 4.38e-2 |
Macrophage | C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 2.76e-2 |
Macrophage | C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.55e-2 |
Macrophage | C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.80e-3 |
Stromal cell | C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 4.06e-2 |
Stromal cell | CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 4.56e-2 |
Stromal cell | CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 3.90e-2 |
Stromal cell | CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 3.99e-3 |
Stromal cell | CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 7.09e-3 |
Macrophage | CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 2.29e-2 |
Macrophage | CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 3.99e-3 |
Macrophage | CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.44e-3 |
Macrophage | CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.39e-3 |
Smooth muscle cell | CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 4.51e-2 |
Endothelial cell | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.72e-2 |
Endothelial cell (APC) | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.10e-2 |
Endothelial cell (APC) | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 3.28e-2 |
Macrophage | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 2.17e-2 |
Macrophage | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 3.32e-2 |
Macrophage | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 4.83e-2 |
Macrophage | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 5.55e-3 |
Stromal cell | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 1.81e-2 |
Stromal cell | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.24e-2 |
Smooth muscle cell | CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 1.05e-2 |
Macrophage | CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.12e-2 |
Endothelial cell | CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.24e-2 |
Macrophage | CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 2.15e-2 |
Macrophage | CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 2.51e-2 |
Macrophage | CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.23e-3 |
Macrophage | CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.70e-3 |
Stromal cell | CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 2.51e-2 |
Stromal cell | CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.94e-2 |
Stromal cell | CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.93e-2 |
Macrophage | Kallikrein11 | kallikrein-11 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.94e-2 |
Macrophage | Kallikrein11 | kallikrein-11 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 6.48e-3 |
Macrophage | Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 2.60e-2 |
Macrophage | Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.55e-2 |
Macrophage | Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 6.48e-3 |
Stromal cell | IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 4.06e-2 |
Stromal cell | IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.29e-2 |
Macrophage | IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 5.30e-3 |
Macrophage | IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.80e-3 |
Smooth muscle cell | IL 12 | interleukin 12 receptor subunit beta-1 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 3.10e-2 |
Macrophage | IL 12 | interleukin 12 receptor subunit beta-1 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.12e-2 |
Macrophage | IL 12 | interleukin 12 receptor subunit beta-1 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.80e-3 |
Stromal cell | IL 12 | interleukin 12 receptor subunit beta-1 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.29e-2 |
Stromal cell | Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 2.51e-2 |
Stromal cell | Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.95e-2 |
Macrophage | Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 1.09e-2 |
Macrophage | Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.24e-3 |
Macrophage | Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 7.37e-4 |
Stromal cell | E-selectin | E-selectin levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 1.68e-2 |
Macrophage | E-selectin | E-selectin levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.94e-2 |
Macrophage | E-selectin | E-selectin levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 3.48e-3 |
Stromal cell | Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 4.20e-2 |
Stromal cell | Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 5.79e-3 |
Stromal cell | Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 6.42e-3 |
Stromal cell | Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.41e-2 |
Stromal cell | Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.93e-2 |
Macrophage | Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 8.06e-3 |
Macrophage | Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.41e-2 |
Macrophage | Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 5.88e-3 |
Endothelial cell (APC) | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 5.00e-2 | 8.06e-3 |
Endothelial cell (APC) | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 1.00e-2 | 8.16e-4 |
Endothelial cell (APC) | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 1.00e-3 | 2.07e-2 |
Endothelial cell (APC) | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 1.00e-4 | 3.17e-2 |
Stromal cell | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 5.00e-2 | 8.06e-3 |
Stromal cell | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 1.00e-2 | 4.31e-2 |
Endothelial cell (APC) | Steroid sensitive nephrotic syndrome | Childhood steroid-sensitive nephrotic syndrome | ETC | Debiec H | 2018 | 132 | 2,000 | 1.00e-2 | 2.42e-2 |
Endothelial cell | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 1.28e-2 |
Endothelial cell | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 1.31e-2 |
Endothelial cell (APC) | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 5.28e-4 |
Endothelial cell (APC) | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 6.82e-4 |
Endothelial cell (APC) | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-3 | 1.21e-2 |
Fibroblast | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 1.28e-2 |
Fibroblast | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 1.87e-2 |
Stromal cell | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 6.82e-3 |
Stromal cell | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 6.82e-4 |
Stromal cell | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-4 | 2.59e-2 |
Macrophage | Snoring | Snoring male | ETC | Campos AI | 2020 | 90,806 | 99,165 | 1.00e-4 | 3.99e-2 |
Fibroblast | Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 5.00e-2 | 1.19e-2 |
Endothelial cell | Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 5.00e-2 | 4.40e-2 |
Endothelial cell | Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-3 | 2.23e-3 |
Endothelial cell | Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-4 | 5.26e-3 |
Endothelial cell (APC) | Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 5.00e-2 | 2.62e-2 |
Endothelial cell (APC) | Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-2 | 8.67e-3 |
Endothelial cell (APC) | Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-3 | 7.60e-3 |
Endothelial cell (APC) | Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-4 | 5.26e-3 |
Endothelial cell (APC) | Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-5 | 3.56e-2 |
Stromal cell | Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 5.00e-2 | 1.48e-3 |
Stromal cell | Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-2 | 1.45e-3 |
Stromal cell | Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-3 | 1.34e-4 |
Smooth muscle cell | COVID-19 Host Genetics | hospitalized covid vs. not hospitalized covid (EA) | ETC | covid19hg | 2020 | 928 | 2028 | 5.00e-2 | 3.60e-3 |
Endothelial cell (APC) | COVID-19 Host Genetics | hospitalized covid vs. not hospitalized covid (EA) | ETC | covid19hg | 2020 | 928 | 2028 | 1.00e-3 | 3.86e-2 |
Endothelial cell (APC) | COVID-19 Host Genetics | predicted covid from self-reported symptoms vs. predicted or self-reported non-covid (EA) | ETC | covid19hg | 2020 | 1865 | 29174 | 5.00e-2 | 4.37e-2 |
Endothelial cell (APC) | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 5.00e-2 | 2.89e-2 |
Endothelial cell (APC) | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-4 | 3.32e-2 |
Endothelial cell (APC) | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-5 | 2.37e-2 |
Endothelial cell | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-4 | 3.32e-2 |
Macrophage | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-4 | 1.18e-3 |
Endothelial cell (APC) | COVID-19 | COVID-19 UKBB EUR tested (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 5,455 | 5.00e-2 | 1.55e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.